0001213900-20-036191.txt : 20201110 0001213900-20-036191.hdr.sgml : 20201110 20201110163337 ACCESSION NUMBER: 0001213900-20-036191 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 201301639 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 10-Q 1 f10q0920_hoththerapeutics.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission File Number: 001-38803

Hoth Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada		82-1553794
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1 Rockefeller Plaza, Suite 1039
New York, NY		10020
(Address of principal executive offices)		(Zip Code)

(646) 756-2997

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		HOTH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at November 9, 2020 was 13,437,473.

Table of Contents

		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Condensed Consolidated Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019	1

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019 (Unaudited)	2

	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2020 and 2019 (Unaudited)	3

	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (Unaudited)	5

	Notes to the Condensed Consolidated Financial Statements (Unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4.	Controls and Procedures	23

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3.	Defaults Upon Senior Securities	24

Item 4.	Mine Safety Disclosures	24

Item 5.	Other Information	24

Item 6.	Exhibits	25

Signatures		26

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

●

our business strategies;

●

the timing of regulatory submissions;

●

our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;

●

risks relating to the timing and costs of clinical trials, the timing and costs of other expenses;

●

risks related to market acceptance of products;

●

the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole;

●

intellectual property risks;

●

risks associated with our reliance on third party organizations;

●

our competitive position;

●

our industry environment;

●

our anticipated financial and operating results, including anticipated sources of revenues;

●

assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches;

●

management’s expectation with respect to future acquisitions;

●

statements regarding our goals, intensions, plans and expectations, including the introduction of new products and markets; and

●

our cash needs and financing plans.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

Hoth Therapeutics, Inc.

Condensed Consolidated Balance Sheets

	September 30,			December 31,
	2020			2019
	(Unaudited)
ASSETS
Current assets
Cash	$	4,120,565		$	1,690,866
Marketable equity securities, at fair value		1,290,022			803,664
Prepaid expenses		79,563			110,072
Deferred offering cost		-			30,484
Total current assets		5,490,150			2,635,086

Note receivable		50,000			-
Property and equipment, net		124			1,043
Investment in joint venture		410,000			-
Restricted cash		-			200,000
Total assets	$	5,950,274		$	2,836,129

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	22,919		$	403,885
Accrued expenses		132,452			36,236
Accrued license fee - current portion		132,500			-
Total current liabilities		287,871			440,121

Accrued license fee		285,000			-
Total liabilities		572,871			440,121

Commitments and contingencies

Stockholders’ equity
Preferred stock, $0.0001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		-			-
Series A Convertible Preferred Stock, $0.0001 par value, 1,897,250 and 5,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		-			-
Common stock, $0.0001 par value, 75,000,000 shares authorized, 13,435,901 and 10,119,844 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		1,343			1,012
Additional paid-in-capital		24,036,222			14,610,638
Accumulated deficit		(18,656,671	)		(12,215,642	)
Accumulated other comprehensive loss		(3,491	)		-
Total stockholders’ equity		5,377,403			2,396,008
Total liabilities and stockholders’ equity	$	5,950,274		$	2,836,129

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Hoth Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019

Operating costs and expenses
Research and development	$	517,839		$	490,266		$	2,092,763		$	1,013,950
Research and development - licenses acquired (including stock-based compensation)		231,090			50,000			625,605			70,000
Compensation and related expenses (including stock-based compensation)		667,694			336,838			1,225,090			791,773
Professional fees (including stock-based compensation)		620,620			643,311			2,176,683			1,481,675
Rent		7,525			8,354			18,533			23,617
Other expenses		122,063			171,675			360,424			416,380
Total operating expenses		2,166,831			1,700,444			6,499,098			3,797,395
Loss from operations		(2,166,831	)		(1,700,444	)		(6,499,098	)		(3,797,395	)

Other income
Other income, net		49,908			4,412			58,069			4,412
Total other income		49,908			4,412			58,069			4,412

Net loss	$	(2,116,923	)	$	(1,696,032	)	$	(6,441,029	)	$	(3,792,983	)

Weighted average number of common shares outstanding, basic and diluted		13,434,884			9,886,759			12,001,987			8,842,905

Net loss per share, basic and diluted	$	(0.16	)	$	(0.17	)	$	(0.54	)	$	(0.43	)

Net loss	$	(2,116,923	)	$	(1,696,032	)	$	(6,441,029	)	$	(3,792,983	)
Other comprehensive loss
Foreign currency translation adjustment		(2,829	)		-			(3,491	)		-
Total comprehensive loss	$	(2,119,752	)	$	(1,696,032	)	$	(6,444,520	)	$	(3,792,983	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Hoth Therapeutics, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

For the Three Months Ended September 30, 2020

	Common Stock				Additional Paid-in		Accumulated			Cumulative Translation			Total Stockholders’
	Shares		Amount		Capital		Deficit			Adjustment			Equity
Balance at June 30, 2020		13,433,267	$	1,343	$	23,375,090	$	(16,539,748	)	$	(662	)	$	6,836,023
Stock-based compensation		2,634		-		661,132		-			-			661,132
Cumulative translation adjustment		-		-		-		-			(2,829	)		(2,829	)
Net loss		-		-		-		(2,116,923	)		-			(2,116,923	)
Balance at September 30, 2020		13,435,901	$	1,343	$	24,036,222	$	(18,656,671	)	$	(3,491	)	$	5,377,403

For the Three Months Ended September 30, 2019

	Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at June 30, 2019		-	$	-		9,668,256	$	967	$	10,795,410	$	(6,607,957	)	$	4,188,420
Issuance common stock and warrants, net of offering cost		-		-		407,424		41		1,610,089		-			1,610,130
Stock-based compensation		-		-		42,082		4		206,756		-			206,760
Net loss		-		-		-		-		-		(1,696,032	)		(1,696,032	)
Balance at September 30, 2019		-	$	-		10,117,762	$	1,012	$	12,612,255	$	(8,303,989	)	$	4,309,278

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Hoth Therapeutics, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

For the Nine Months Ended September 30, 2020

	Common Stock						Additional Paid-in		Accumulated			Cumulative Translation			Total Stockholders’
	Shares			Amount			Capital		Deficit			Adjustment			Equity
Balance at December 31, 2019		10,119,844		$	1,012		$	14,610,638	$	(12,215,642	)	$	-		$	2,396,008
Issuance of common stock and warrants (net of offering costs of $806,243)		1,449,275			145			4,193,611		-			-			4,193,756
Issuance of common stock (net of offering costs of $525,000)		1,818,182			182			4,474,818		-			-			4,475,000
Cancellation of common stock		(15,000	)		(2	)		2		-			-			-
Warrant exercise		56,250			6			56,244		-			-			56,250
Stock-based compensation		7,350			-			700,909		-			-			700,909
Cumulative translation adjustment		-			-			-		-			(3,491	)		(3,491	)
Net loss		-			-			-		(6,441,029	)		-			(6,441,029	)
Balance at September 30, 2020		13,435,901		$	1,343		$	24,036,222	$	(18,656,671	)	$	(3,491	)	$	5,377,403

For the Nine Months Ended September 30, 2019

	Convertible Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares			Amount			Shares		Amount		Capital			Deficit			Equity
Balance at December 31, 2018		3,102,480		$	310			5,071,400	$	507	$	4,665,154		$	(4,511,006	)	$	154,965
Conversion of preferred stock to common stock upon completion of the IPO		(3,102,480	)		(310	)		3,102,480		310		-			-			-
Issuance common stock in the IPO, net of offering cost		-			-			1,250,000		125		5,840,042			-			5,840,167
Issuance common stock and warrants, net of offering cost								407,424		41		1,610,089			-			1,610,130
Cashless warrant exercise		-			-			223,877		22		(22	)		-			-
Warrant exercise								16,333		2		161			-			163
Stock-based compensation		-			-			46,248		5		496,831			-			496,836
Net loss		-			-			-		-		-			(3,792,983	)		(3,792,983	)
Balance at September 30, 2019		-		$	-			10,117,762	$	1,012	$	12,612,255		$	(8,303,989	)	$	4,309,278

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Hoth Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities
Net loss	$	(6,441,029	)	$	(3,792,983	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		919			916
Research and development-acquired license, expensed		525,000			70,000
Stock-based compensation		700,909			496,836
Realized gain on marketable securities		11,060			-
Unrealized gain on marketable securities		(49,024	)		(4,398	)
Changes in assets and liabilities:
Prepaid expenses		30,509			(101,540	)
Accounts payable		(254,266	)		(116,967	)
Net cash used in operating activities		(5,475,922	)		(3,448,136	)

Cash flows from investing activities
Purchase of investments in joint venture		(410,000	)		-
Purchase of research and development licenses		(107,500	)		(70,000	)
Purchase of marketable securities		(1,500,000	)		(800,000	)
Purchase of convertible promissory note in Isoprene		(50,000	)		-
Sale of marketable securities		1,051,606			-
Net cash used in investing activities		(1,015,894	)		(870,000	)

Cash flows from financing activities
Proceeds from issuance of common stock in the IPO, net of offering cost		-			5,840,167
Proceeds from issuance common stock and warrants, net of offering cost		4,193,756			1,610,130
Proceeds from issuance common stock, net of offering cost		4,475,000			-
Proceeds from exercise of warrants		56,250			163
Net cash provided by financing activities		8,725,006			7,450,460

Effect of exchange rate changes on cash and cash equivalents		(3,491	)		-

Net increase in cash		2,229,699			3,132,324
Cash and restricted cash, beginning of period		1,890,866			282,621

Cash and restricted cash, end of period	$	4,120,565		$	3,414,945

Non-cash investing and financing activities
Conversion of preferred stock to common stock upon completion of the IPO	$	-		$	310
Cancellation and retirement of common stock	$	2		$	-
Cashless warrant exercise	$	-		$	22

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1-Organization and description of business operations

Hoth Therapeutics, Inc. (together with its wholly-owned subsidiary, Hoth Therapeutics Australia Pty Ltd., the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017. The Company’s primary asset is a license agreement with the University of Cincinnati that was assigned to the Company by Chelexa Biosciences, Inc. pursuant to which the University of Cincinnati has granted the Company an exclusive license to use its BioLexa Platform (as defined herein), a proprietary, patented, drug compound platform. The license enables the Company to develop the platform for all indications in humans. The Company’s initial focus will be on the treatment of eczema and other dermatological indications. The BioLexa Platform combines a U.S. Food and Drug Administration (“FDA”) approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. To the Company’s knowledge, it is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur.

Liquidity and capital resources

Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern, requires management to evaluate the Company’s ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the condensed consolidated financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised.

The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions.

The Company’s current cash is sufficient to fund operations for at least the next 12 months; however, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for the Company’s existing and new product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed.

Note 2-Significant accounting policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 2, 2020.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary, Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All intercompany balances and transactions have been eliminated.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to the stock-based compensation, the valuation of investments and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Significant Accounting Policies

There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as filed with the SEC on March 2, 2020.

Restricted Cash

The following table provides a summary of the Company’s cash and restricted cash total as presented in the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 and a reconciliation of cash and restricted cash from consolidated balance sheet to consolidated statements of cash flow for the year ended December 31, 2019:

	September 30, 2020		September 30, 2019		December 31, 2019
Cash	$	4,120,565	$	3,214,945	$	1,690,866
Restricted cash		-		200,000		200,000
Total cash and restricted cash	$	4,120,565	$	3,414,945	$	1,890,866

The $0.2 million restricted cash was deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement. On May 29, 2020, the $0.2 million restricted cash in the escrow account was returned to the Company.

Net loss per share

Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:

	As of September 30,
Potentially dilutive securities	2020		2019
Warrants		1,235,266		1,032,692
Options		739,212		-
Non-vested restricted stock units		12,516		15,282
Total		1,986,994		1,047,974

Investment in joint venture

Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: Accounting for Limited Partnership Investments (codified in Accounting Standards Codification (“ASC”) 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3% to 5% are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint venture is further described in Note of 7 these financial statements.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Recent accounting pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company’s condensed consolidated financial statements.

Note 3-License agreements

The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during three and nine months ended September 30, 2020 and 2019:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
The George Washington University	$	153,590	$	2,500	$	195,605	$	2,500
Isoprene Pharmaceuticals, Inc.		30,000		-		30,000		-
University of Cincinnati		17,500		7,500		35,000		7,500
University of Maryland and Isoprene Pharmaceuticals, Inc.		-		-		-		10,000
Virginia Commonwealth University		30,000		-		365,000		-
Zylö Therapeutics, Inc.		-		40,000		-		50,000
	$	231,090	$	50,000	$	625,605	$	70,000

Chelexa Biosciences, Inc. and the University of Cincinnati

On May 14, 2020, the Company entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Chelexa Biosciences, Inc. (“Chelexa”) pursuant to which Chelexa assigned to the Company its rights and obligations in and to and liabilities under its license agreement with the University of Cincinnati dated February 27, 2013, as amended (the “University of Cincinnati License Agreement”). In consideration for the assignment, the Company agreed to forgive all amounts due to it by Chelexa and to pay to Chelexa certain royalty payments.

In connection with the Assignment Agreement, on May 14, 2020, the Company entered into a novation agreement (the “Novation Agreement”) with Chelexa and the University of Cincinnati pursuant to which the parties agreed that the Company would be substituted in place of Chelexa with respect to the rights and obligations of Chelexa set forth in the University of Cincinnati License Agreement.

In connection with the Assignment Agreement, on May 14, 2020, the Company entered into a royalty agreement (the “Royalty Agreement”) with Chelexa pursuant to which the Company shall pay Chelexa sales-based royalties at percentages which range from mid to high single digits, with high sales volumes being subject to lower royalty rates and total milestone payments of $3.5 million.

Pursuant to the University of Cincinnati License Agreement, the Company was granted an exclusive license to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the “BioLexa Platform” or “BioLexa”). In addition, the University of Cincinnati granted the Company the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, offer for sale, and sell products based upon the BioLexa Platform. The term of such agreement will expire on the later of April 16, 2034 and the last to expire patent in the patent rights granted to the Company (the “Term”). The Company shall, in its sole discretion, have the first right of refusal to renew the Term. The Company is subject to total milestone payments of $6,000, royalty payments, annual license maintenance fees, and has agreed to pay the University of Cincinnati for certain out-of-pocket expenses including, but not limited to, payments for patent prosecution.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The George Washington University

Effective as of June 1, 2019, the Company and The George Washington University (“GW”) entered into a sponsored research agreement (the “Sponsored Research Agreement”), as amended on July 29, 2019 and May 29, 2020, with respect to the exploration of the potential use of HT-001 for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients. Pursuant to the terms of the Sponsored Research Agreement, GW granted the Company a non-exclusive license to certain of GW’s intellectual property. The Company has agreed to pay GW for all costs incurred in connection with the research; provided, however, such costs shall not exceed approximately $0.5 million. The Sponsored Research Agreement shall terminate on June 30, 2021. The Sponsored Research Agreement may be terminated by either party upon 30 days written notice.

On June 28, 2019 (the “Effective Date”), the Company and GW entered into a research option agreement (the “Research Option Agreement”) pursuant to which GW granted the Company an option (the “Option”) until April 30, 2020 to acquire an exclusive license to certain products made or used by the Company (the “GW Licensed Product”) that involve certain patents owned by GW (the “Licensed Patents”). On February 1, 2020, the Company exercised the Option and entered into a patent license agreement (the “Patent License Agreement”) with GW. On the Effective Date, the Company paid GW $2,500, and on February 27, 2020, the Company paid GW $10,000 as a license initiation fee. Until the first commercial sale of the GW Licensed Product, the Company shall pay (i) $75,000 per year for the development and commercialization of the GW Licensed Product, (ii) $2,000 for license maintenance fees on the first anniversary of the Effective Date and (iii) $5,000 for license maintenance fees commencing on the second anniversary of the Effective Date and thereafter. Furthermore, the Company shall be required to pay GW a sublicense fee equal to a certain percentage of the sum of payments plus the fair market value of all other consideration of any kind received by the Company from sublicensees during each quarter as follows: a 40% sublicense fee until the first anniversary of the Effective Date, a 30% sublicense fee until the third anniversary of the Effective Date and a 20% sublicense fee after the third anniversary of the Effective Date; provided, however, such sublicense fee shall exclude certain fees paid to the Company such as certain royalties, equity investments, loan proceeds and sponsored research funding. The Company shall also pay GW milestone payments of up to an aggregate of $90,000 and sales-based royalties at a low single digit percentage, subject to certain minimum royalty requirements. In addition, during each Option Exercise Period and Renewal Period (as defined in the Research Option Agreement) the Company shall pay GW, on a quarterly basis, for all costs and expenses related to the GW Licensed Patents (the “Patent Costs”).

On August 7, 2020 (the “GW Effective Date”), the Company entered into a Patent License Agreement (the “GW Patent License Agreement”) with the GW. Pursuant to the GW Patent License Agreement, GW granted the Company an exclusive, worldwide, royalty bearing license to certain intellectual property that can be used to develop a device designed to detect the presence of SARS-CoV-2. Specifically, the GW Patent License Agreement permits the Company to make, have made, use, import, offer for sale and sell Licensed Products (as defined in the GW Patent License Agreement) in the field of virus sensing and detection. The GW Patent License Agreement shall commence on the GW Effective Date and shall continue until the later of: (a) the expiration or abandonment of the last patent to expire or become abandoned of the Patent Rights (as defined in the GW Patent License Agreement); or (b) ten years after the first Sale (as defined in the GW Patent License Agreement) of the first Licensed Product if no patent has issued from the Patent Rights, unless terminated earlier pursuant to the terms of the agreement. Pursuant to the GW Patent License Agreement, the Company shall pay GW: (i) an upfront license initiation fee, (ii) annual maintenance fees commencing on the first anniversary of the GW Effective Date, (iii) milestone payments ranging from the low to mid five figures, (iv) running royalty payments at a middle single digit percentage of Net Sales (as defined in the GW License Agreement), (iv) quarterly minimum payments ranging from the low four figures for the first four quarters after the first sale to low five figures commencing three years after the first sale and (v) an annual diligence fee of high five figures. In addition, the Company has agreed to reimburse GW for certain past and future patent filing and prosecution costs.

On September 17, 2020, the Company entered into a Sponsored Research Agreement (the “Agreement”) with GW effective as of September 1, 2020 (the “Agreement Effective Date”). The Agreement relates to the development of a diagnostic device for the detection of SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection. The Agreement commences on the Agreement Effective Date and terminates on July 31, 2021 unless such term is extended by the parties. Pursuant to the Agreement, the Company shall pay GW up to a mid-six figure fee for all research costs.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

University of Maryland and Isoprene Pharmaceuticals, Inc.

On March 8, 2019, the Company entered into a commercial evaluation sublicense and option agreement (the “Commercial Evaluation Sublicense and Option Agreement”) with the University of Maryland, Baltimore (“UMB”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”). Pursuant to the agreement, the Company paid an initial option and material access fee of $5,000 to UMB and $5,000 to Isoprene. In the event that Isoprene enters into a master license agreement with UMB (the “MLA”), UMB shall permit Isoprene to grant an exclusive option to the Company to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “Isoprene-Hoth Option”); provided, however, in the event Isoprene does not enter into the MLA, UMB may grant the Company an option to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “UMB-Hoth Option”). If the Company exercises the Isoprene-Hoth Option, it shall pay Isoprene an option exercise fee of $20,000. If the Company exercises the UMB-Hoth Option, it shall pay UMB an option exercise fee of $20,000.

On July 30, 2020 (the “Isoprene Effective Date”), the Company entered into a Sublicense Agreement (the “Isoprene Sublicense Agreement”) with Isoprene pursuant to the Commercial Evaluation Sublicense and Option Agreement. Pursuant to the Isoprene Sublicense Agreement, Isoprene granted the Company an exclusive sublicense to certain intellectual property (i) to make, have made, use, sell, offer to sell and import certain licensed products, (ii) in connection therewith, to use certain inventions and licensed materials and (iii) to practice the Patent Rights (as defined in the Isoprene Sublicense Agreement) for the treatment of dermatological conditions or diseases. The Isoprene Sublicense Agreement will continue on a country-by-country basis until the expiration of the last to expire of the Patent Rights in such country, unless earlier terminated pursuant to the Isoprene Sublicense Agreement (the “Isoprene Term”). Pursuant to the Isoprene Sublicense Agreement, the Company shall pay Isoprene, among other things, (i) a license fee, (ii) a royalty rate at a middle single digit percentage, (iii) milestone payments of up to $1,375,000 and (iv) revenue interest at a low single digit percentage based on the net revenue of covered products sold by Isoprene during the Isoprene Term.

North Carolina State University

On November 20, 2019 (the “NCSU Effective Date”), the Company entered into a license agreement with North Carolina State University (“NCSU”) pursuant to which NCSU granted the Company an exclusive license to, among other things, develop, make, use, offer and sell certain licensed products throughout the world with respect to HT-004 for treating allergic diseases. The term of the license agreement shall commence on the NCSU Effective Date and shall continue until the date of the expiration of the last to expire patent right granted pursuant to the license agreement unless terminated earlier pursuant to the terms of the agreement. Pursuant to the terms of the license agreement, the Company paid NCSU a one-time license fee $25,000 and is also required to pay (i) sales-based royalties at a low single digit percentage, (ii) minimum royalties ranging from $0 to $50,000 and (iii) milestone payments of up to $585,000.

University of Cincinnati

On May 18, 2018, the Company entered into an exclusive license agreement with the University of Cincinnati for a patented, novel genetic marker for food allergies. The genetic marker licensed by the Company from the University of Cincinnati may be used to (i) identify at risk infants in predicting food allergies, including peanut and milk allergies, (ii) identify a person’s predisposition to an allergic reaction, thereby avoiding such reaction and (iii) determine an individual’s propensity to develop atopic dermatitis, such as eczema. The Company intends to utilize the genetic marker for purposes of determining an individual’s propensity to develop eczema as well as to identify and treat allergies in at-risk infants.

Pursuant to the terms of the exclusive license agreement, the Company paid the University of Cincinnati a minimum annual royalty fee of $5,000 and has agreed to pay the University of Cincinnati an annual license fee of $5,000 initially due and payable within 30 days of the one year anniversary of the exclusive license agreement and every year thereafter and milestone payments of up to $120,000. The exclusive license agreement will continue until the later of (i) the date upon which a valid claim pursuant to the terms of the exclusive license agreement expires or (ii) 10 years after the first commercial sale or unless earlier terminated pursuant to the terms of the exclusive license agreement.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Virginia Commonwealth University

On May 18, 2020 (the “VCU Effective Date”), the Company entered into an Exclusive License Agreement (the “VCU License Agreement”) with the Virginia Commonwealth University Intellectual Property Foundation (“VCU”). Pursuant to the VCU License Agreement, VCU granted the Company an exclusive, royalty bearing license to a novel peptide developed by researchers at VCU that may be used to slow the transmission of SARS-CoV-2 (the “VCU Licensed Patent”) and a non-exclusive royalty bearing, worldwide license with respect to the Licensed Technical Information Patents (as defined in the VCU License Agreement) to make, have made, use, offer to sell, sell and import the Licensed Products (as defined in the VCU License Agreement) and perform the Licensed Services (as defined in the VCU License Agreement). The VCU License Agreement shall commence on the VCU Effective Date and shall continue until the expiration of the last to expire VCU Licensed Patent unless terminated earlier pursuant to the terms of the agreement. Pursuant to the VCU License Agreement, the Company shall pay VCU: (i) an upfront license issue fee, (ii) running royalty payments at a low single digit percentage of Net Sales (as defined in the VCU License Agreement), (iii) annual maintenance fees commencing on the first anniversary of the VCU Effective Date, (iv) annual minimum payments ranging from the mid five figures to low six figures commencing on the second anniversary of the VCU Effective Date and (v) milestone payments ranging from the mid five figures to low six figures. In addition, the Company has agreed to reimburse VCU for certain patent filing and prosecution costs. During the nine months ended September 30, 2020, the Company paid the signing fee of $50,000 upon execution of the VCU License Agreement. Pursuant to the VCU License Agreement, the Company has agreed to pay VCU an annual license fee and to make annual minimum payments.

On June 29, 2020, the Company entered into a Sponsored Project Agreement (the “VCU Sponsored Project Agreement”) with VCU for the development of a potential COVID-19 treatment using the license to a novel peptide granted to the Company by VCU. The VCU Sponsored Project Agreement shall terminate on January 9, 2021, unless earlier terminated pursuant to the terms thereof.

Zylö Therapeutics Inc.

On August 19, 2019 (the “Zylö Effective Date”), the Company entered into an exclusive sublicense agreement (the “Sublicense Agreement”) with Zylö Therapeutics, Inc. (“Zylö”) pursuant to which Zylö granted to the Company an exclusive sublicense to the Licensed Patent Rights (as defined in the Sublicense Agreement) and the Licensed Technology (as defined in the Sublicense Agreement) to, among other things, develop, make and sell the Licensed Products (as defined in the Sublicense Agreement) and to practice the Licensed Technology in the United States and Canada for any and all uses within the Field. “Field” means all therapeutic uses related to lupus in human beings, subject to the Field Expansion Rights (as defined in the Sublicense Agreement). The term of the Sublicense Agreement shall commence on the Zylö Effective Date and shall continue until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product in such country and (ii) expiration of the last to expire Valid Claim (as defined in the Sublicense Agreement) of the Licensed Patent Rights that would be infringed by the composition, use or sale of such Licensed Product in such country. Pursuant to the terms of the Sublicense Agreement, the Company and Zylö shall establish a joint development committee to plan, review, coordinate and oversee the Company’s development activities with respect to the Licensed Products in the Field. Pursuant to the Sublicense Agreement, the Company paid Zylö an upfront license fee of $50,000 and is required to pay Zylö (i) sales-based royalties at percentages which range from high single digits to low double digits, with low sales volumes being subject to lower royalty rates; and (ii) total milestone payments of up to $13.5 million. In addition, in connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 30,000 shares of Zylö’s Class B common stock for $60,000. Effective January 1, 2018, the Company adopted ASU 2016-01 concerning recognition and measurement of financial assets and financial liabilities. In adopting this new guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for its investment in Zylö.

Note 4-Note Receivable

Pursuant to Isoprene Sublicense Agreement dated July 30, 2020, the Company made an investment of $50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred in a private financing that results in gross proceeds of at least $5 million. “Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization Isoprene immediately prior to the conversion of the Isoprene Note. In the event a Change of Control occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Qualified Financing, the Isoprene Note may be converted into such number of shares of Isoprene’s common stock equal to the quotient obtained by dividing (i) the balance of the Isoprene Note by (ii) two times the fair market value of a share of Isoprene common stock as set for in the acquisition agreement pertaining to such Change of Control.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 5-Related Party

A former director of the Company, is also the Executive Chairman of Chelexa. During the nine months ended September 30, 2020, such former director received $22,500 in cash compensation for services provided as a member of the Company’s board of directors (the “Board” or “Board of Directors”). On September 30, 2020, this director resigned as a member of the Company’s Board of Directors.

A former director of the Company, is also the Chief Executive Officer, Principal Accounting and Financial Officer and a member of the board of directors of AIkido Pharma Inc. (formerly known as Spherix Incorporated). During the nine months ended September 30, 2020, such former director received $8,700 in cash compensation for services provided as a member of the Company’s Board of Directors. On April 15, 2020, this director resigned as a member of the Company’s Board of Directors and its committees. Options issued to him expired on July 15, 2020, which is further described in Note of 8 these financial statements.

During the nine months ended September 30, 2020, the Company issued an aggregate of 7,350 shares of the Company’s common stock to members of the Company’s Board for services rendered.

Note 6-Fair Value of Financial Assets

FASB ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:	Quoted prices in active markets for identical assets or liabilities.

Level 2:	Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:	Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

The Company’s financial instruments include cash, marketable securities and accounts payable. The fair value of these financial instruments approximates their carrying value due to the short-term nature. With respect to the Company’s investment in a joint venture, the fair value of this investment approximates its carrying value due to the minimal transaction activity within this joint venture.

The following table presents the Company’s assets and liabilities that are measured at fair value at September 30, 2020 and December 31, 2019:

	Fair value measured at September 30, 2020
	Total at September 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2020		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities - mutual funds	$	1,290,022	$	1,290,022	$	-	$	-

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

	Fair value measured at December 31, 2019
	Total at December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2019		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities - mutual funds	$	803,664	$	803,664	$	-	$	-

Fair Value Measurements on a Non-Recurring Basis

The Company measures the fair value of certain assets on a non-recurring basis, generally quarterly, annually, or when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. These assets include the investment in joint venture accounted for using the equity method and investment in Zylö for using cost method. When the Company determines that the carrying value of these assets may not be recoverable, the Company records the assets at fair value with the loss recognized in the condensed consolidated statements of operations and comprehensive loss. In such cases, the Company measures the fair value of these assets using the techniques discussed above under the Level 3 category.

Note 7-Investment in HaloVax

On March 23, 2020, the Company entered into a Development and Royalty Agreement (the “Development and Royalty Agreement”) with Voltron Therapeutics, Inc. (“Voltron”) to form a joint venture entity named HaloVax, LLC (“HaloVax”) to jointly develop potential product candidates for the prevention of COVID-19 based upon certain technology that had been exclusively licensed by Voltron from The General Hospital Corporation (d/b/a Massachusetts General Hospital). Pursuant to the Development and Royalty Agreement, the Company is entitled to receive sales-based royalties. In addition, pursuant to the terms of the Development and Royalty Agreement, on March 23, 2020, the Company and HaloVax entered into a Membership Interest Purchase Agreement pursuant to which the Company purchased 5% of HaloVax’s outstanding membership interests for $250,000 on March 27, 2020 (the “Initial Closing Date”) and shall have the option to purchase up to an additional 25% of HaloVax’s membership interests (for $3,000,000 (inclusive of the $250,000)), which option shall expire 30 days after the Initial Closing Date. On May 28, 2020, the Company entered into a membership interest purchase agreement to purchase 1% of HaloVax’s outstanding membership interest for a purchase price of $100,000. As such, the Company accounts for those investments under the equity method. There was no significant change in HaloVax’s operations from March 23, 2020 to September 30, 2020.

Note 8-Stockholders’ Equity

Common Stock

On January 17, 2020, pursuant to the termination and general release agreement between the Company and FON Consulting LLC, 15,000 of the shares originally issued to FON Consulting LLC were cancelled.

On February 5, 2020, the Company issued 12,500 shares of common stock upon exercise of warrants issued to an investor on January 19, 2018, which resulted in gross proceeds of $12,500.

On March 6, 2020, the Company issued 25,000 shares of common stock upon exercise of the warrants issued to an investor on December 13, 2017, which resulted in gross proceeds of $25,000.

On April 15, 2020, the Company issued each of two directors 3,333 shares of the Company’s common stock pursuant to the Company’s 2018 Equity Incentive Plan which shares vest in 36 equal monthly installments with the first installment vesting on the date of grant.

On May 18, 2020, the Company issued 6,250 shares of common stock upon exercise of warrants issued to an investor on February 2, 2018, which resulted in gross proceeds of $6,250.

On June 3, 2020, the Company issued 12,500 shares of common stock upon exercise of warrants issued to an investor on November 20, 2017, which resulted in gross proceeds of $12,500.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

During the nine months ended September 30, 2020, the Company issued an aggregate of 7,350 shares of the Company’s common stock to members of the Company’s Board for services rendered.

Public Offering of Securities

On March 24, 2020 (the “UA Effective Date”), the Company entered into an underwriting agreement with Laidlaw & Company (UK) Ltd. (“Laidlaw”), the representative of the underwriters, relating to a best efforts underwritten public offering of 1,449,275 shares (the “Shares”) of the Company’s common stock at a public offering price of $3.45 per Share. The Company received net proceeds of approximately $4.2 million, after deducting the underwriting discount and offering expenses.

In connection with the offering, the Company issued Laidlaw warrants to purchase up to 72,464 shares of the Company’s common stock, representing 5% of the aggregate number of Shares sold in the offering. The warrants will be exercisable for a period of five years from the UA Effective Date at a price per share equal to $4.14 (120% of the public offering price per Share) and are exercisable on a “cashless” basis. The Company has reimbursed Laidlaw for certain of its out-of-pocket expenses incurred in connection with the offering.

On May 21, 2020 (the “Benchmark Effective Date”), the Company entered into an underwriting agreement with The Benchmark Company, LLC (“Benchmark”), as representative of the several underwriters, relating to the public offering of 1,818,182 shares of the Company’s common stock at a price to the public of $2.75 per share. The Company received net proceeds of approximately $4.5 million, after deducting the underwriting discount and offering expenses.

In connection with the offering, the Company issued Benchmark warrants to purchase 90,909 shares of the Company’s common stock. The warrants are exercisable for a period of five years commencing six months from the Benchmark Effective Date at a price per share equal to $2.75 and are exercisable on a “cashless” basis.

Restricted Stock Awards

A summary of the Company’s restricted stock grants under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) during the nine months ended September 30, 2020 is as follows:

	Number of Units			Weighted Average Grant Day Fair Value
Nonvested at December 31, 2019		13,200		$	0.25
Granted		6,666			3.00
Vested		(7,350	)		0.66
Nonvested at September 30, 2020		12,516		$	1.47

As of September 30, 2020, the Company had approximately $12,000 of unrecognized stock-based compensation expense which was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards is approximately 1.47 years at September 30, 2020.

Stock Options

On July 8, 2020, the compensation committee of the Board of Directors approved the issuance of ten-year options to purchase up to 49,212 shares of the Company’s common stock at an exercise price of $2.54 per share pursuant to the 2018 Plan to an advisor for services to be rendered. The aggregate grant date fair value of these options was approximately $0.1 million. The stock options vested in full upon grant.

On July 15, 2020, an option to purchase up to 35,000 shares of the Company’s common stock originally issued on December 24, 2019 to a former board member expired after such board member’s resignation from the board effective as of on April 15, 2020.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

On July 21, 2020, the Company’s Board of Directors approved the issuance of ten-year options to purchase an aggregate of 200,000 shares of the Company’s common stock at an exercise price of $3.05 per share pursuant to the 2018 Plan to directors and certain officers of the Company in consideration for services rendered. The aggregate grant date fair value of these options was approximately $0.5 million. The stock options vested in full upon grant.

A summary of option activity under the Company’s stock option plan for nine months ended September 30, 2020 is presented below:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2019		525,000		$	5.32	$	457,250		9.4
Employee options issued		200,000			3.05		-		9.8
Non - employee options issued		49,212			2.54		-		9.8
Forfeited		(35,000	)		-		-		-
Outstanding as of September 30, 2020		739,212		$	4.52	$	-		9.0
Options vested and exercisable		739,212		$	4.52	$	-		9.0

Warrants

Pursuant to the Patent License Agreement between the Company and GW dated February 1, 2020, on February 27, 2020 (the “February Warrant Date of Issuance”), the Company issued GW warrants (the “February Warrants”) to purchase up to 22,988 shares of the Company’s common stock at an exercise price of $4.35 per share. The February Warrants vest as follows: 20% upon the February Warrant Date of Issuance and the balance, or 80% of the February Warrants shall vest in four equal annual installments of 20% on each anniversary of the February Warrant Date of Issuance.

Pursuant to the GW Patent License Agreement between the Company and GW dated August 7, 2020, on August 10, 2020 (the “August Warrant Date of Issuance”), the Company issued GW ten year warrants (the “August Warrants”) to purchase up to 72,463 shares of the Company’s common stock at an exercise price of $2.76 per share. The August Warrants vest as follows: 20% upon the August Warrant Date of Issuance and the balance, or 80% of the August Warrants shall vest in four equal annual installments of 20% on each anniversary of the August Warrant Date of Issuance.

In connection with the public offering of securities discussed above, the Company granted to Laidlaw and Benchmark warrants to purchase up to 72,464 and 90,909 shares of the Company’s common stock, respectively.

A summary of warrant activity for the nine months ended September 30, 2020 is as follows:

	Number of Warrants			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2019		1,032,692		$	2.91	$	3,725,745		4.2
Issued		258,824			3.28		-		5.2
Exercised		(56,250	)		1.00		-		-
Outstanding as of September 30, 2020		1,235,266		$	3.07	$	696,334		3.7
Warrants exercisable as of September 30, 2020		1,158,906		$	3.07	$	696,334		3.7

The Company has determined that the warrants should be accounted as a component of stockholders’ equity.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Stock Based Compensation

Stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019 was as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Employee stock option awards	$	487,963	$	-	$	487,963	$	199,182
Non-employee stock option awards		100,104		-		100,104		-
Employee restricted stock awards		4,475		2,210		12,237		8,499
Non-employee restricted stock awards		-		204,550		-		204,550
Non-employee stock warrant awards		68,590		-		100,605		84,605
	$	661,132	$	206,760	$	700,909	$	496,836

Employee related stock-based compensation is recognized as “compensation and related expenses” and non-employee related stock-based compensation is recognized as “professional fees” or “research and development - licenses acquired” in the condensed statements of operations and comprehensive loss.

Note 9-Commitments and contingencies

Office lease

The Company leases office space for approximately $2,000 a month. Rent expense for the nine months ended September 30, 2020 and 2019 was approximately $19,000 and $24,000, respectively.

Litigation

From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.

Note 10-Risk and Uncertainties

The outbreak of the novel Coronavirus (COVID-19) has evolved into a global pandemic. The Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts the Company’s business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its impact, among others.

As a result of the continuing spread of the Coronavirus, certain aspects of the Company’s business operations have been delayed, and the Company may be subject to additional delays or interruptions. Specifically, as a result of the shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development activities of certain of the Company’s partners have been affected, resulting in delays to the Company’s clinical trials, and the Company can provide no assurance as to when such trials will resume at this time or the revised timeline to complete trials once resumed.

Furthermore, site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If the Coronavirus continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and the Company may be unable to conduct its clinical trials. Further, if the spread of the Coronavirus pandemic continues and our operations are adversely impacted, the Company risks a delay, default and/or nonperformance under existing agreements which may increase our costs. These cost increases may not be fully recoverable or adequately covered by insurance.

Hoth Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Infections and deaths related to the pandemic may disrupt the United States’ healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval with respect to, the Company’s clinical trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of the Company’s clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the Company’s product candidates.

The Company currently utilizes third parties to, among other things, manufacture raw materials. If any third-party party in the supply chain for materials used in the production of the Company’s product candidates are adversely impacted by restrictions resulting from the Coronavirus outbreak, the Company’s supply chain may be disrupted, limiting the Company’s ability to manufacture its product candidates for its clinical trials and research and development operations.

The spread of the Coronavirus, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on the Company’s business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the Coronavirus could materially and adversely affect the Company’s business and the value of its common stock.

The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s operations, and the Company will continue to monitor the situation closely.

Note 11-Subsequent events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements other than disclosed.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion and analysis of our financial condition and results of operations together with and our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as amended by our Quarterly Reports on Form 10-Q. All amounts in this report are in U.S. dollars, unless otherwise noted.

Overview

We are a clinical-stage biopharmaceutical company incorporated in May 2017 focused on developing new generation therapies for dermatological disorders. We believe that our pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma and acne.

Our primary asset is a license agreement with the University of Cincinnati which was assigned to us by Chelexa Biosciences, Inc. on May 14, 2020 pursuant to which the University of Cincinnati has granted us an exclusive license to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the “BioLexa Platform” or “BioLexa”). The license enables us to develop the platform for any indications in humans. Our initial focus will be on the treatment of eczema through the application of a topical cream. Although our initial focus will be on the treatment of eczema, we intend to develop a second topical cream which, upon application, is intended to reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing aesthetic dermatology procedures. The BioLexa Platform combines a U.S. Food and Drug Administration (“FDA”) approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. To management’s knowledge, it is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur.

We intend to initially use the BioLexa Platform to develop two different topical cream products: (i) a product to treat eczema and (ii) a product that reduces post-procedure infections, accelerates healing and improves clinical outcomes for patients undergoing aesthetic dermatology procedures. Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis. We are concentrating our effort and resources to develop the BioLexa Platform, utilizing our novel formulation and approach for these two markets.

The BioLexa Platform has achieved positive results in its initial pre-clinical studies conducted at the University of Miami. BioLexa’s formulation is a new topical dosage form “repurposing” the antibiotic, enabling it to be developed for use in patients following a special regulatory pathway codified in Section 505(b)(2) of the FDA rules. Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act was enacted to enable sponsors to seek New Drug Application (“NDA”) approval for novel repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will be able to rely upon all of the publicly available safety and toxicology data with respect to gentamicin and zinc chelator in our FDA submissions. We will be required to conduct a Phase 2 study to show the safety of the combination in humans and after such Phase 2 study will be required to proceed to Phase 3 pivotal clinical trials. We believe that this path will dramatically reduce the required clinical development effort, costs and risks as compared to what would be required of us if we were required to conduct pre-clinical safety, toxicology and animal studies together with Phase 1 human safety trials required for new chemical entities which are not eligible to be reviewed pursuant to the Section 505(b)(2) regulatory pathway. We estimate that by using the Section 505(b)(2) regulatory pathway, that the clinical development process may be five to six years shorter than is required for a new chemical entity, and the FDA approval process may be six to nine months shorter than the typical eighteen month period, which we believe may result in lower development costs and shorter development time. As of the date hereof, we have not submitted an NDA to the FDA. In September 2018, we attended the first of a planned series of meetings with the FDA to review the requirements for submission and activation of an investigational new drug application (“IND”) with respect to the BioLexa Platform for use in eczema. In preparation for such pre-IND meeting, we prepared and presented to the FDA our proposed Phase 2 clinical trial plan for the treatment of eczema in patients over the age of one year old. As part of our pre-IND meeting, the FDA provided us with general guidance with respect to specific animal studies, dosing schedules and suggested human safety studies before we commence clinical trials in pediatric or adult patients. We completed all of the suggested studies in early 2020 and planned for the BioLexa clinical trial phase of development in Australia. We have engaged Novotech (Australia) Pty Limited (“Novotech”) as our local clinical research organization in Australia. Novotech will provide clinical management, data management, biostatistical, medical monitoring, medical writing, pharmacovigilance, regulatory, biodesk and other related services to support clinical trial of BioLexa in humans. On August 13, 2020, we submitted our application for approval to start our clinical trial of BioLexa to the Belberry Human Research Ethics Committee in Australia. We have also engaged Camargo Pharmaceutical Services, LLC (“Camargo”) to assist us with the FDA process required for Section 505(b)(2) applications. Specifically, Camargo has provided and will continue to provide advice and guidance relative to the IND preparation phase for the BioLexa Platform. Camargo will assist us with the refinement of our non-clinical, clinical, clinical pharmacology and biopharmaceutics strategy incorporating the preliminary feedback we received from the FDA during our pre-IND meeting.

We believe that the key elements for our market success with respect to BioLexa include:

	●	the proprietary formulation of two FDA-approved drugs to treat bacterial proliferation reduces development time and costs by giving us the ability to rely on safety and efficacy data from the two approved drugs;

	●	our proprietary formulation is not a topical corticosteroid, and may not be subject to the same FDA black box warning issues as most commonly prescribed treatments currently in use; and

	●	a recent peer-reviewed publication titled “Staphylococcal Bacteria May Cause Eczema, Study Reveals”, published by Dr. Herbert B. Allen, highlights that staph-induced biofilms are the root cause of flare-ups in eczema. Our BioLexa product candidate has been demonstrated to prevent the formation of these biofilms with the promise of delaying or completely arresting flare-ups, rather than merely treating symptoms of a flare-up already underway.

In addition to our license agreement with the University of Cincinnati, we entered into the following agreements:

●

an exclusive license agreement with the University of Cincinnati for a patented, novel genetic marker for food allergies. The genetic marker licensed by us from the University of Cincinnati may be used to (i) identify at risk infants in predicting food allergies, including peanut and milk allergies, (ii) identify a person’s predisposition to an allergic reaction, thereby avoiding such reaction and (iii) determine an individual’s propensity to develop atopic dermatitis, such as eczema. We intend to utilize the genetic marker for purposes of determining an individual’s propensity to develop eczema as well as to identify and treat allergies in at-risk infants.

●

an exclusive sublicense agreement (the “Sublicense Agreement”) with Zylö Therapeutics, Inc. (“Zylö”) pursuant to which Zylö granted us an exclusive sublicense to the Licensed Patent Rights (as defined in the Sublicense Agreement) and the Licensed Technology (as defined in the Sublicense Agreement) to, among other things, develop, make and sell the Licensed Products (as defined in the Sublicense Agreement) and to practice the Licensed Technology in the United States and Canada for any and all therapeutic uses related to lupus in human beings, subject to the Field Expansion Rights (as defined in the Sublicense Agreement).

●

a license agreement with North Carolina State University (“NCSU”) pursuant to which NCSU granted us an exclusive license to, among other things, develop, make, use, offer and sell certain licensed products throughout the world with respect to HT-004 for treating allergic diseases.

●

a patent license agreement with The George Washington University (“GW”) pursuant to which GW granted us a license to certain patent rights to, among other things, make, use, offer and sell certain licensed products throughout the world with respect to HT-001 as used in treating side effects from drugs used for the treatment of cancer.

●

a patent license agreement with GW pursuant to which GW granted us a license to certain patent rights to, among other things, make, use, offer and sell certain licensed products throughout the world with respect to an On-The-Go Sars-CoV-2 Testing Device System.

●

a patent sublicense agreement with Isoprene Pharmaceutics, Inc. (“Isoprene”) pursuant to which Isoprene granted us an exclusive sublicense to certain patent rights to, among other things, make, use, offer and sell certain licensed products throughout the world with respect to HT-003 as used to treat dermatological conditions or diseases and dermatology oncology indications.

●

an exclusive license agreement (the “VCU License Agreement”) with the Virginia Commonwealth University Intellectual Property Foundation (“VCU”) pursuant to which VCU granted us an exclusive, royalty bearing license (the “VCU License”) to a novel peptide developed by researchers at VCU that may be used to slow the transmission of SARS-CoV-2 and a non-exclusive royalty bearing, worldwide license with respect to certain licensed technical information patents to make, have made, use, offer to sell, sell and import the Licensed Products (as defined in the VCU License Agreement) and perform the Licensed Services (as defined in the VCU License Agreement). In addition, we entered into a Sponsored Project Agreement with VCU for the development of a potential COVID-19 treatment using the VCU License to a novel peptide granted to us by VCU.

In order to generate revenue from our product candidates, we will need to sell our product candidates either through distribution partnerships or through our own sales efforts. Prior to selling our product candidates, we will need to receive FDA approval of our NDA for each indication that we intend to treat. The first indication we are seeking approval for is the BioLexa Platform for treating eczema. We intend to submit our NDA for such indication by mid to late 2022 with approval of such NDA anticipated to be in 2022; however, no assurances can be given that we will receive approval of the NDA in a timely manner, if at all.

Agreements with Chelexa BioSciences, Inc.

On May 14, 2020, we entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Chelexa Biosciences, Inc. (“Chelexa”) pursuant to which Chelexa assigned to us its rights and obligations in and to and liabilities under its license agreement with the University of Cincinnati dated February 27, 2013, as amended (the “University of Cincinnati License Agreement”). In consideration for the assignment, we agreed to forgive all amounts due to us by Chelexa and pay to Chelexa certain royalty payments as set forth in the Royalty Agreement (as defined below).

In connection with the Assignment Agreement, on May 14, 2020, we entered into a novation agreement (the “Novation Agreement”) with Chelexa and the University of Cincinnati pursuant to which the parties agreed that we would be substituted in place of Chelexa with respect to the rights and obligations of Chelexa set forth in the University of Cincinnati License Agreement.

In connection with the Assignment Agreement, on May 14, 2020, we entered into a royalty agreement (the “Royalty Agreement”) with Chelexa pursuant to which we shall pay Chelexa sales-based royalties at percentages which range from mid to high single digits, with high sales volumes being subject to lower royalty rates and total milestone payments of $3.5 million. The Royalty Agreement will continue until the earlier of May 31, 2025 or the last to expire patent in the Patent Rights (as defined in the Royalty Agreement), unless sooner terminated pursuant to the terms of the Royalty Agreement. In addition, the Royalty Agreement may be terminated by Chelexa upon written notice to the Company.

COVID-19

The outbreak of the novel Coronavirus (COVID-19) has evolved into a global pandemic, and the Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its impact, among others.

As a result of the continuing spread of the Coronavirus, certain aspects of our business operations have been delayed, and we may be subject to additional delays or interruptions. Specifically, as a result of the shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development activities of certain of our partners have been affected, resulting in delays to our clinical trials, and we can provide no assurance as to when such trials will resume at this time or the revised timeline to complete trials once resumed.

Results of Operations

Comparison of the Three Months Ended September 30, 2020 and 2019

Operating Costs and Expenses

Research and Development Expenses

For the three months ended September 30, 2020, research and development expenses were approximately $0.8 million, of which approximately $0.2 million was related to licenses acquired and approximately $0.5 million was related to other research and development expenses.

For the three months ended September 30, 2019, research and development expenses were approximately $0.5 million, of which $40,000 was related to the Zylö Sublicense Agreement and approximately $0.5 million was related to other research and development expenses.

We expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with the following:

●

employee-related expenses, which include salaries and benefits, and rent expenses;

●

fees and other expenses related to in-licensed products and technology;

●

expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical activities;

●

the cost of acquiring and manufacturing clinical trial materials; and

●

costs associated with non-clinical activities and regulatory approvals.

Compensation, Professional Fees, Rent and Other (“General and Administrative Expenses”)

For the three months ended September 30, 2020, General and Administrative Expenses were approximately $1.4 million, which primarily consisted of approximately $0.7 million related to payroll expenses and stock-based compensation, approximately $0.6 million for professional fees and approximately $0.1 million for rent and other expenses.

For the three months ended September 30, 2019, General and Administrative Expenses were approximately $1.2 million, which primarily consisted of approximately $0.3 million related to payroll expenses and stock-based compensation, approximately $0.6 million for professional fees and approximately $0.2 million for other expenses.

We anticipate that our General and Administrative Expenses will increase in future periods, reflecting continued and increasing costs associated with:

●

support of our research and development activities;

●

stock compensation granted to key employees and non-employees;

●

support of business development activities; and

●

increased professional fees and other costs associated with regulatory requirements.

Comparison of the Nine Months Ended September 30, 2020 and 2019

Operating Costs and Expenses

Research and Development Expenses

For the nine months ended September 30, 2020, research and development expenses were approximately $2.7 million, of which approximately $0.6 million was related to licenses acquired and approximately $2.1 million was related to other research and development expenses.

For the nine months ended September 30, 2019, research and development expenses were approximately $1.1 million which primarily consisted of $50,000 related to the Zylö Sublicense Agreement, an aggregate of $10,000 related to a license acquired from the University of Maryland Baltimore and Isoprene and approximately $1.0 million related to other research and development expenses.

Compensation, Professional Fees, Rent and Other

For the nine months ended September 30, 2020, General and Administrative Expenses were approximately $3.8 million, which primarily consisted of approximately $1.2 million related to payroll expenses and stock-based compensation, approximately $2.2 million for professional fees and approximately $0.4 million for other expenses.

For the nine months ended September 30, 2019, General and Administrative Expenses were approximately $2.7 million, which primarily consisted of approximately $0.8 million related to payroll expenses and stock-based compensation, approximately $1.5 million for professional fees and approximately $0.4 million for other expenses.

Liquidity and Capital Resources

We have incurred substantial operating losses since inception, and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2020, we had cash of approximately $4.1 million, marketable securities of approximately $1.3 million, working capital of approximately $5.2 million and an accumulated deficit of approximately $18.7 million.

Our current cash is sufficient to fund operations for at least the next 12 months; however, we will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for our existing and new product candidates. If such funding is not available, or not available on terms acceptable to us, our current development plan and plans for expansion of our general and administrative infrastructure may be curtailed.

Cash Flows from Operating Activities

For the nine months ended September 30, 2020, net cash used in operations was approximately $5.5 million, which primarily resulted from a net loss of approximately $6.4 million and changes in operating assets and liabilities of approximately $0.2 million, partially offset by approximately $0.5 million research and development expense related with license acquisitions and $0.6 million stock-based compensation.

For the nine months ended September 30, 2019, net cash used in operations was approximately $3.4 million, which primarily resulted from a net loss of approximately $3.8 million and changes in operating assets and liabilities of approximately $0.2 million, partially offset by approximately $0.5 million stock-based compensation.

Cash Flows from Investing Activities

For the nine months ended September 30, 2020, net cash used in investing activities was approximately $1.0 million, which was primarily related to the purchase of marketable securities of $1.5 million and purchase of investments in HaloVax, LLC and Zylö of approximately $0.4 million, partially offset by the sale of marketable securities of approximately $1.1 million.

For the nine months ended September 30, 2019, net cash used in investing activities was approximately $0.9 million, which was related to the purchase of marketable securities of $0.8 million and the purchase of research and development licenses of $70,000.

Cash Flows from Financing Activities

For the nine months ended September 30, 2020, net cash provided by financing activities was approximately $8.7 million. The cash provided by financing activities primarily resulted from approximately $8.7 million in net proceeds from the issuance of common stock and warrants.

For the nine months ended September 30, 2019, net cash provided by financing activities was approximately $7.5 million, including approximately $0.2 million restricted cash. The cash provided by financing activities primarily resulted from approximately $5.8 million in net proceeds from our initial public offering (the “IPO”) and approximately $1.6 million in net proceeds from a private offering of an aggregate of 407,474 units with each unit consisting of one share of our common stock and a warrant to purchase one-half share of our common stock. On February 20, 2019, we closed the IPO pursuant to which we issued 1,250,000 shares of our common stock for net proceeds of approximately $5.8 million, after deducting underwriting discounts and commissions and offering expenses. The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.

Off-Balance Sheet Arrangements; Commitments and Contractual Obligations

As of September 30, 2020, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations.

JOBS Act

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the IPO; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2020, our disclosure controls and procedures were effective.

Changes in Internal Control

There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

ITEM 1A. RISK FACTORS.

Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report, as amended by our Quarterly Reports on Form 10-Q (collectively, the “Reports”). There have been no material changes in our risk factors from those previously disclosed in our Reports. You should carefully consider the risks described in our Reports, which could materially affect our business, financial condition or future results. The risks described in our Reports are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the quarter months ended September 30, 2020, the Company issued an aggregate of 2,634 shares of the Company’s common stock to members of the Company’s Board for services rendered.

The foregoing issuances were exempt from registration under Section 4(a)(2) of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit No.		Description

10.1##		Sponsored Project Agreement by and between the Company and Virginia Commonwealth University (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on July 2, 2020)

10.2##		Sublicense Agreement by and between the Company and Isoprene Pharmaceutics, Inc. dated July 30, 2020 (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on August 5, 2020)

10.3+		Employment Agreement by and between the Company and Stefanie Johns dated August 28, 2020 (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on August 31, 2020)

10.4##		Sponsored Research Agreement by and between the Company and the George Washington University (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on September 21, 2020)

31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

##	Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

+	Indicates a management contract or any compensatory plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HOTH THERAPEUTICS, INC.

Date: November 10, 2020	By:	/s/ Robb Knie
		Robb Knie, Chief Executive Officer (Principal Executive Officer)

Date: November 10, 2020	By:	/s/ David Briones
		David Briones, Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 f10q0920ex31-1_hoththera.htm CERTIFICATION

Exhibit 31.1

Certification of Chief Executive Officer of Hoth Therapeutics, Inc.
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robb Knie, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Hoth Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2020	/s/ Robb Knie
	Robb Knie, Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 f10q0920ex31-2_hoththera.htm CERTIFICATION

Exhibit 31.2

Certification of Chief Financial Officer of Hoth Therapeutics, Inc.
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David Briones, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Hoth Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2020	/s/ David Briones
	David Briones, Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 f10q0920ex32-1_hoththera.htm CERTIFICATION

Exhibit 32.1

Statement of Chief Executive Officer
Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

The Company’s quarterly report on Form 10-Q for the period ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2020	/s/ Robb Knie
	Robb Knie,
	Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 f10q0920ex32-2_hoththera.htm CERTIFICATION

Exhibit 32.2

Statement of Chief Financial Officer
Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, David Briones, Chief Financial Officer of Hoth Therapeutics, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2020	/s/ David Briones
	David Briones, Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 6 hoth-20200930.xml XBRL INSTANCE FILE 0001711786 2020-01-01 2020-09-30 0001711786 2020-11-09 0001711786 2020-09-30 0001711786 2019-12-31 0001711786 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001711786 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001711786 2020-07-01 2020-09-30 0001711786 2019-07-01 2019-09-30 0001711786 2019-01-01 2019-09-30 0001711786 us-gaap:CommonStockMember 2020-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001711786 us-gaap:RetainedEarningsMember 2020-06-30 0001711786 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-06-30 0001711786 2020-06-30 0001711786 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001711786 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001711786 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-07-01 2020-09-30 0001711786 us-gaap:CommonStockMember 2020-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001711786 us-gaap:RetainedEarningsMember 2020-09-30 0001711786 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-09-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-06-30 0001711786 us-gaap:CommonStockMember 2019-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001711786 us-gaap:RetainedEarningsMember 2019-06-30 0001711786 2019-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-07-01 2019-09-30 0001711786 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001711786 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-09-30 0001711786 us-gaap:CommonStockMember 2019-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001711786 us-gaap:RetainedEarningsMember 2019-09-30 0001711786 2019-09-30 0001711786 us-gaap:CommonStockMember 2019-12-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001711786 us-gaap:RetainedEarningsMember 2019-12-31 0001711786 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001711786 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001711786 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001711786 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-01-01 2020-09-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001711786 us-gaap:CommonStockMember 2018-12-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001711786 us-gaap:RetainedEarningsMember 2018-12-31 0001711786 2018-12-31 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0001711786 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001711786 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001711786 2020-05-29 0001711786 srt:MinimumMember 2020-09-30 0001711786 srt:MaximumMember 2020-09-30 0001711786 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001711786 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001711786 hoth:OptionsMember 2020-01-01 2020-09-30 0001711786 hoth:NonvestedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001711786 hoth:NonvestedRestrictedStockUnitsMember 2019-01-01 2019-09-30 0001711786 hoth:AssignmentAgreementMember 2020-05-01 2020-05-14 0001711786 hoth:ChelexaBioSciencesIncMember hoth:UniversityOfCincinnatiMember 2020-05-01 2020-05-14 0001711786 hoth:GeorgeWashingtonUniversityMember 2019-05-22 2019-06-01 0001711786 hoth:LicensedPatentMember hoth:GeorgeWashingtonUniversityMember 2020-02-01 0001711786 hoth:GeorgeWashingtonUniversityMember 2020-02-01 2020-02-27 0001711786 2019-03-01 2019-03-08 0001711786 hoth:IsopreneHothOptionMember 2019-03-01 2019-03-08 0001711786 hoth:UMDHothOptionMember 2019-03-01 2019-03-08 0001711786 hoth:IsopreneSublicenseAgreementMember 2020-07-01 2020-07-30 0001711786 hoth:NorthCarolinaStateUniversityMember 2019-11-01 2019-11-20 0001711786 srt:MinimumMember hoth:NorthCarolinaStateUniversityMember 2019-11-01 2019-11-20 0001711786 srt:MaximumMember hoth:NorthCarolinaStateUniversityMember 2019-11-01 2019-11-20 0001711786 hoth:LicenseAgreementMember hoth:UniversityOfCincinnatiMember 2018-05-01 2018-05-18 0001711786 hoth:VirginiaCommonwealthUniversityMember 2020-01-01 2020-09-30 0001711786 hoth:ZyloTherapeuticsIncMember 2019-08-01 2019-08-19 0001711786 hoth:GeorgeWashingtonUniversityPatentLicenseAgreementMember 2020-07-01 2020-09-30 0001711786 hoth:GeorgeWashingtonUniversityPatentLicenseAgreementMember 2019-07-01 2019-09-30 0001711786 hoth:GeorgeWashingtonUniversityPatentLicenseAgreementMember 2020-01-01 2020-09-30 0001711786 hoth:GeorgeWashingtonUniversityPatentLicenseAgreementMember 2019-01-01 2019-09-30 0001711786 hoth:IsoprenePharmaceuticalsMember 2020-07-01 2020-09-30 0001711786 hoth:IsoprenePharmaceuticalsMember 2019-07-01 2019-09-30 0001711786 hoth:IsoprenePharmaceuticalsMember 2020-01-01 2020-09-30 0001711786 hoth:IsoprenePharmaceuticalsMember 2019-01-01 2019-09-30 0001711786 hoth:UniversityOfCincinnatiMember 2020-07-01 2020-09-30 0001711786 hoth:UniversityOfCincinnatiMember 2019-07-01 2019-09-30 0001711786 hoth:UniversityOfCincinnatiMember 2020-01-01 2020-09-30 0001711786 hoth:UniversityOfCincinnatiMember 2019-01-01 2019-09-30 0001711786 hoth:UniversityofMarylandandIsoprenePharmaceuticalsIncMember 2020-07-01 2020-09-30 0001711786 hoth:UniversityofMarylandandIsoprenePharmaceuticalsIncMember 2019-07-01 2019-09-30 0001711786 hoth:UniversityofMarylandandIsoprenePharmaceuticalsIncMember 2020-01-01 2020-09-30 0001711786 hoth:UniversityofMarylandandIsoprenePharmaceuticalsIncMember 2019-01-01 2019-09-30 0001711786 hoth:VirginiaCommonwealthUniversityMember 2020-07-01 2020-09-30 0001711786 hoth:VirginiaCommonwealthUniversityMember 2019-07-01 2019-09-30 0001711786 hoth:VirginiaCommonwealthUniversityMember 2019-01-01 2019-09-30 0001711786 hoth:ZyloTherapeuticsIncMember 2020-07-01 2020-09-30 0001711786 hoth:ZyloTherapeuticsIncMember 2019-07-01 2019-09-30 0001711786 hoth:ZyloTherapeuticsIncMember 2020-01-01 2020-09-30 0001711786 hoth:ZyloTherapeuticsIncMember 2019-01-01 2019-09-30 0001711786 srt:DirectorMember 2020-09-30 0001711786 srt:DirectorMember hoth:AIkidoPharmaIncMember 2020-09-30 0001711786 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001711786 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001711786 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001711786 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001711786 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001711786 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001711786 2020-03-01 2020-03-23 0001711786 2020-05-01 2020-05-28 0001711786 2020-01-01 2020-01-17 0001711786 us-gaap:CommonStockMember 2020-02-01 2020-02-05 0001711786 us-gaap:CommonStockMember 2020-03-01 2020-03-06 0001711786 us-gaap:CommonStockMember 2020-04-01 2020-04-15 0001711786 us-gaap:CommonStockMember 2020-05-01 2020-05-18 0001711786 us-gaap:CommonStockMember 2020-06-01 2020-06-03 0001711786 hoth:PlacementAgentWarrantsMember 2020-03-24 0001711786 hoth:PlacementAgentWarrantsMember 2020-03-01 2020-03-24 0001711786 hoth:PlacementAgentWarrantsMember 2020-05-21 0001711786 hoth:PlacementAgentWarrantsMember 2020-05-01 2020-05-21 0001711786 hoth:TwoZeroOneEightEquityIncentivePlanMember 2020-05-01 2020-05-21 0001711786 srt:ControllerMember hoth:TwoZeroOneEightEquityIncentivePlanMember 2020-09-30 0001711786 srt:DirectorMember 2020-01-01 2020-09-30 0001711786 hoth:StockOptionsMember 2020-07-01 2020-07-08 0001711786 hoth:StockOptionsMember 2020-07-08 0001711786 hoth:StockOptionsMember 2020-07-01 2020-07-08 0001711786 hoth:StockOptionsMember 2020-07-01 2020-07-15 0001711786 hoth:StockOptionsMember 2020-07-01 2020-07-21 0001711786 hoth:StockOptionsMember 2020-07-21 0001711786 us-gaap:WarrantMember 2020-02-01 2020-02-27 0001711786 us-gaap:WarrantMember 2020-02-27 0001711786 us-gaap:WarrantMember 2020-08-07 2020-08-10 0001711786 us-gaap:WarrantMember 2020-08-10 0001711786 srt:MinimumMember us-gaap:WarrantMember 2020-02-27 0001711786 srt:MaximumMember us-gaap:WarrantMember 2020-02-27 0001711786 us-gaap:RestrictedStockMember 2019-12-31 0001711786 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember 2020-09-30 0001711786 us-gaap:WarrantMember 2020-09-30 0001711786 us-gaap:RestrictedStockMember us-gaap:EmployeeStockMember 2020-07-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeStockOptionAwardsMember 2020-07-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeStockOptionAwardsMember 2019-07-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeStockOptionAwardsMember 2020-01-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeStockOptionAwardsMember 2019-01-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:EmployeeRestrictedStockAwardsMember 2020-07-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:EmployeeRestrictedStockAwardsMember 2019-07-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:EmployeeRestrictedStockAwardsMember 2020-01-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:EmployeeRestrictedStockAwardsMember 2019-01-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeRestrictedStockAwardsMember 2020-07-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeRestrictedStockAwardsMember 2019-07-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeRestrictedStockAwardsMember 2020-01-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonemployeeRestrictedStockAwardsMember 2019-01-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonEmployeeWarrantAwardsMember 2020-07-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonEmployeeWarrantAwardsMember 2019-07-01 2019-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonEmployeeWarrantAwardsMember 2020-01-01 2020-09-30 0001711786 us-gaap:RestrictedStockMember hoth:NonEmployeeWarrantAwardsMember 2019-01-01 2019-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure false --12-31 Q3 2020 2020-09-30 10-Q 0001711786 Yes true false 001-38803 Non-accelerated Filer NV Yes Hoth Therapeutics, Inc. false true 13437473

4120565

1690866

1290022

803664

79563

110072

30484

5490150

2635086

50000

124

1043

410000

200000

5950274

2836129

22919

403885

132452

36236

132500

287871

440121

285000

572871

440121

1343

1012

24036222

14610638

-18656671

-12215642

-3491

5377403

2396008

5950274

2836129

0.0001

5000000

0.0001

1897250

5000000

0.0001

75000000

13435901

10119844

13435901

10119844

517839

490266

2092763

1013950

231090 50000 625605 70000 667694 336838 1225090 791773

620620

643311

2176683

1481675

7525 8354 18533 23617

122063

171675

360424

416380

2166831

1700444

6499098

3797395

-2166831

-1700444

-6499098

-3797395

49908

4412

58069

4412

49908

4412

58069

4412

-2116923

-1696032

-6441029

-3792983

13434884

9886759

12001987

8842905

-0.16

-0.17

-0.54

-0.43

-2829

-3491

-2119752

-1696032

-6444520

-3792983

13433267

1343

23375090

-16539748

-662

6836023

2634

661132

-2829

-2116923

13435901

1343

24036222

-18656671

-3491

5377403

9668256

967

10795410

-6607957

4188420

407424 41 1610089 1610130

42082

206756

206760

-1696032

10117762

1012

12612255

-8303989

4309278

10119844

1012

14610638

-12215642

2396008

1449275 145 4193611 4193756

1818182

182

4474818

4475000

-15000 -2 2 56250 6 56244 56250

7350

700909

-3491

-6441029

3102480

310

5071400

507

4665154

-4511006

154965

-3102480 -310 3102480 310

1250000

125

5840042

5840167

407424 41 1610089 1610130 223877 22 -22 16333 2 161 163

46248

496831

496836

-3792983

806243

525000

919

916

525000 70000

700909

496836

-11060

49024

4398

-30509

101540

-254266

-116967

-5475922

-3448136

-410000

107500

70000

1500000 800000 50000 1051606

-1015894

-870000

5840167

4193756 1610130 4475000

56250

163

8725006

7450460

-3491

2229699

3132324

1890866

282621

4120565

3414945

310 2 22

Note 1-Organization and description of business operations Hoth Therapeutics, Inc. (together with its wholly-owned subsidiary, Hoth Therapeutics Australia Pty Ltd., the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017. The Company’s primary asset is a license agreement with the University of Cincinnati that was assigned to the Company by Chelexa Biosciences, Inc. pursuant to which the University of Cincinnati has granted the Company an exclusive license to use its BioLexa Platform (as defined herein), a proprietary, patented, drug compound platform. The license enables the Company to develop the platform for all indications in humans. The Company’s initial focus will be on the treatment of eczema and other dermatological indications. The BioLexa Platform combines a U.S. Food and Drug Administration (“FDA”) approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. To the Company’s knowledge, it is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur. Liquidity and capital resources Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern, requires management to evaluate the Company’s ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the condensed consolidated financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised. The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions. The Company’s current cash is sufficient to fund operations for at least the next 12 months; however, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for the Company’s existing and new product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed.

Note 2-Significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 2, 2020. The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary, Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All intercompany balances and transactions have been eliminated. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to the stock-based compensation, the valuation of investments and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Significant Accounting Policies  There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as filed with the SEC on March 2, 2020. Restricted Cash The following table provides a summary of the Company’s cash and restricted cash total as presented in the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 and a reconciliation of cash and restricted cash from consolidated balance sheet to consolidated statements of cash flow for the year ended December 31, 2019:  <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2019</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,120,565</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,214,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,690,866</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,120,565</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,414,945</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,890,866</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> The $0.2 million restricted cash was deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement. On May 29, 2020, the $0.2 million restricted cash in the escrow account was returned to the Company. Net loss per share Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Potentially dilutive securities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,235,266</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,692</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">739,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-vested restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,516</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,282</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,986,994</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,047,974</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Investment in joint venture Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: Accounting for Limited Partnership Investments (codified in Accounting Standards Codification (“ASC”) 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3% to 5% are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint venture is further described in Note of 7 these financial statements.  Recent accounting pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company’s condensed consolidated financial statements.

Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 2, 2020. The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary, Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All intercompany balances and transactions have been eliminated.

Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to the stock-based compensation, the valuation of investments and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Significant Accounting Policies  There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as filed with the SEC on March 2, 2020.

Restricted Cash The following table provides a summary of the Company’s cash and restricted cash total as presented in the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 and a reconciliation of cash and restricted cash from consolidated balance sheet to consolidated statements of cash flow for the year ended December 31, 2019:  <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2019</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,120,565</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,214,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,690,866</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,120,565</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,414,945</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,890,866</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> The $0.2 million restricted cash was deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement. On May 29, 2020, the $0.2 million restricted cash in the escrow account was returned to the Company.

200000

Net loss per share Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Potentially dilutive securities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,235,266</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,692</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">739,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-vested restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,516</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,282</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,986,994</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,047,974</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

Investment in joint venture Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: Accounting for Limited Partnership Investments (codified in Accounting Standards Codification (“ASC”) 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3% to 5% are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint venture is further described in Note of 7 these financial statements.

0.03

0.05

Recent accounting pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company’s condensed consolidated financial statements.

4120565

3214945

1690866

200000

4120565

3414945

1890866

1235266

1032692

739212

12516

15282

1986994

1047974

Note 3-License agreements The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during three and nine months ended September 30, 2020 and 2019: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">153,590</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">195,605</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Isoprene Pharmaceuticals, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>University of Cincinnati</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">University of Maryland and Isoprene Pharmaceuticals, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Zylö Therapeutics, Inc.</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">231,090</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">50,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">625,605</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">70,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Chelexa Biosciences, Inc. and the University of Cincinnati On May 14, 2020, the Company entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Chelexa Biosciences, Inc. (“Chelexa”) pursuant to which Chelexa assigned to the Company its rights and obligations in and to and liabilities under its license agreement with the University of Cincinnati dated February 27, 2013, as amended (the “University of Cincinnati License Agreement”). In consideration for the assignment, the Company agreed to forgive all amounts due to it by Chelexa and to pay to Chelexa certain royalty payments. In connection with the Assignment Agreement, on May 14, 2020, the Company entered into a novation agreement (the “Novation Agreement”) with Chelexa and the University of Cincinnati pursuant to which the parties agreed that the Company would be substituted in place of Chelexa with respect to the rights and obligations of Chelexa set forth in the University of Cincinnati License Agreement. In connection with the Assignment Agreement, on May 14, 2020, the Company entered into a royalty agreement (the “Royalty Agreement”) with Chelexa pursuant to which the Company shall pay Chelexa sales-based royalties at percentages which range from mid to high single digits, with high sales volumes being subject to lower royalty rates and total milestone payments of $3.5 million. Pursuant to the University of Cincinnati License Agreement, the Company was granted an exclusive license to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the “BioLexa Platform” or “BioLexa”). In addition, the University of Cincinnati granted the Company the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, offer for sale, and sell products based upon the BioLexa Platform. The term of such agreement will expire on the later of April 16, 2034 and the last to expire patent in the patent rights granted to the Company (the “Term”). The Company shall, in its sole discretion, have the first right of refusal to renew the Term. The Company is subject to total milestone payments of $6,000, royalty payments, annual license maintenance fees, and has agreed to pay the University of Cincinnati for certain out-of-pocket expenses including, but not limited to, payments for patent prosecution. The George Washington University Effective as of June 1, 2019, the Company and The George Washington University (“GW”) entered into a sponsored research agreement (the “Sponsored Research Agreement”), as amended on July 29, 2019 and May 29, 2020, with respect to the exploration of the potential use of HT-001 for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients. Pursuant to the terms of the Sponsored Research Agreement, GW granted the Company a non-exclusive license to certain of GW’s intellectual property. The Company has agreed to pay GW for all costs incurred in connection with the research; provided, however, such costs shall not exceed approximately $0.5 million. The Sponsored Research Agreement shall terminate on June 30, 2021. The Sponsored Research Agreement may be terminated by either party upon 30 days written notice. On June 28, 2019 (the “Effective Date”), the Company and GW entered into a research option agreement (the “Research Option Agreement”) pursuant to which GW granted the Company an option (the “Option”) until April 30, 2020 to acquire an exclusive license to certain products made or used by the Company (the “GW Licensed Product”) that involve certain patents owned by GW (the “Licensed Patents”). On February 1, 2020, the Company exercised the Option and entered into a patent license agreement (the “Patent License Agreement”) with GW. On the Effective Date, the Company paid GW $2,500, and on February 27, 2020, the Company paid GW $10,000 as a license initiation fee. Until the first commercial sale of the GW Licensed Product, the Company shall pay (i) $75,000 per year for the development and commercialization of the GW Licensed Product, (ii) $2,000 for license maintenance fees on the first anniversary of the Effective Date and (iii) $5,000 for license maintenance fees commencing on the second anniversary of the Effective Date and thereafter. Furthermore, the Company shall be required to pay GW a sublicense fee equal to a certain percentage of the sum of payments plus the fair market value of all other consideration of any kind received by the Company from sublicensees during each quarter as follows: a 40% sublicense fee until the first anniversary of the Effective Date, a 30% sublicense fee until the third anniversary of the Effective Date and a 20% sublicense fee after the third anniversary of the Effective Date; provided, however, such sublicense fee shall exclude certain fees paid to the Company such as certain royalties, equity investments, loan proceeds and sponsored research funding. The Company shall also pay GW milestone payments of up to an aggregate of $90,000 and sales-based royalties at a low single digit percentage, subject to certain minimum royalty requirements. In addition, during each Option Exercise Period and Renewal Period (as defined in the Research Option Agreement) the Company shall pay GW, on a quarterly basis, for all costs and expenses related to the GW Licensed Patents (the “Patent Costs”). On August 7, 2020 (the “GW Effective Date”), the Company entered into a Patent License Agreement (the “GW Patent License Agreement”) with the GW. Pursuant to the GW Patent License Agreement, GW granted the Company an exclusive, worldwide, royalty bearing license to certain intellectual property that can be used to develop a device designed to detect the presence of SARS-CoV-2. Specifically, the GW Patent License Agreement permits the Company to make, have made, use, import, offer for sale and sell Licensed Products (as defined in the GW Patent License Agreement) in the field of virus sensing and detection. The GW Patent License Agreement shall commence on the GW Effective Date and shall continue until the later of: (a) the expiration or abandonment of the last patent to expire or become abandoned of the Patent Rights (as defined in the GW Patent License Agreement); or (b) ten years after the first Sale (as defined in the GW Patent License Agreement) of the first Licensed Product if no patent has issued from the Patent Rights, unless terminated earlier pursuant to the terms of the agreement. Pursuant to the GW Patent License Agreement, the Company shall pay GW: (i) an upfront license initiation fee, (ii) annual maintenance fees commencing on the first anniversary of the GW Effective Date, (iii) milestone payments ranging from the low to mid five figures, (iv) running royalty payments at a middle single digit percentage of Net Sales (as defined in the GW License Agreement), (iv) quarterly minimum payments ranging from the low four figures for the first four quarters after the first sale to low five figures commencing three years after the first sale and (v) an annual diligence fee of high five figures. In addition, the Company has agreed to reimburse GW for certain past and future patent filing and prosecution costs. On September 17, 2020, the Company entered into a Sponsored Research Agreement (the “Agreement”) with GW effective as of September 1, 2020 (the “Agreement Effective Date”). The Agreement relates to the development of a diagnostic device for the detection of SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection. The Agreement commences on the Agreement Effective Date and terminates on July 31, 2021 unless such term is extended by the parties. Pursuant to the Agreement, the Company shall pay GW up to a mid-six figure fee for all research costs. University of Maryland and Isoprene Pharmaceuticals, Inc. On March 8, 2019, the Company entered into a commercial evaluation sublicense and option agreement (the “Commercial Evaluation Sublicense and Option Agreement”) with the University of Maryland, Baltimore (“UMB”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”). Pursuant to the agreement, the Company paid an initial option and material access fee of $5,000 to UMB and $5,000 to Isoprene. In the event that Isoprene enters into a master license agreement with UMB (the “MLA”), UMB shall permit Isoprene to grant an exclusive option to the Company to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “Isoprene-Hoth Option”); provided, however, in the event Isoprene does not enter into the MLA, UMB may grant the Company an option to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “UMB-Hoth Option”). If the Company exercises the Isoprene-Hoth Option, it shall pay Isoprene an option exercise fee of $20,000. If the Company exercises the UMB-Hoth Option, it shall pay UMB an option exercise fee of $20,000. On July 30, 2020 (the “Isoprene Effective Date”), the Company entered into a Sublicense Agreement (the “Isoprene Sublicense Agreement”) with Isoprene pursuant to the Commercial Evaluation Sublicense and Option Agreement. Pursuant to the Isoprene Sublicense Agreement, Isoprene granted the Company an exclusive sublicense to certain intellectual property (i) to make, have made, use, sell, offer to sell and import certain licensed products, (ii) in connection therewith, to use certain inventions and licensed materials and (iii) to practice the Patent Rights (as defined in the Isoprene Sublicense Agreement) for the treatment of dermatological conditions or diseases. The Isoprene Sublicense Agreement will continue on a country-by-country basis until the expiration of the last to expire of the Patent Rights in such country, unless earlier terminated pursuant to the Isoprene Sublicense Agreement (the “Isoprene Term”). Pursuant to the Isoprene Sublicense Agreement, the Company shall pay Isoprene, among other things, (i) a license fee, (ii) a royalty rate at a middle single digit percentage, (iii) milestone payments of up to $1,375,000 and (iv) revenue interest at a low single digit percentage based on the net revenue of covered products sold by Isoprene during the Isoprene Term. North Carolina State University On November 20, 2019 (the “NCSU Effective Date”), the Company entered into a license agreement with North Carolina State University (“NCSU”) pursuant to which NCSU granted the Company an exclusive license to, among other things, develop, make, use, offer and sell certain licensed products throughout the world with respect to HT-004 for treating allergic diseases. The term of the license agreement shall commence on the NCSU Effective Date and shall continue until the date of the expiration of the last to expire patent right granted pursuant to the license agreement unless terminated earlier pursuant to the terms of the agreement. Pursuant to the terms of the license agreement, the Company paid NCSU a one-time license fee $25,000 and is also required to pay (i) sales-based royalties at a low single digit percentage, (ii) minimum royalties ranging from $0 to $50,000 and (iii) milestone payments of up to $585,000. University of Cincinnati On May 18, 2018, the Company entered into an exclusive license agreement with the University of Cincinnati for a patented, novel genetic marker for food allergies. The genetic marker licensed by the Company from the University of Cincinnati may be used to (i) identify at risk infants in predicting food allergies, including peanut and milk allergies, (ii) identify a person’s predisposition to an allergic reaction, thereby avoiding such reaction and (iii) determine an individual’s propensity to develop atopic dermatitis, such as eczema. The Company intends to utilize the genetic marker for purposes of determining an individual’s propensity to develop eczema as well as to identify and treat allergies in at-risk infants. Pursuant to the terms of the exclusive license agreement, the Company paid the University of Cincinnati a minimum annual royalty fee of $5,000 and has agreed to pay the University of Cincinnati an annual license fee of $5,000 initially due and payable within 30 days of the one year anniversary of the exclusive license agreement and every year thereafter and milestone payments of up to $120,000. The exclusive license agreement will continue until the later of (i) the date upon which a valid claim pursuant to the terms of the exclusive license agreement expires or (ii) 10 years after the first commercial sale or unless earlier terminated pursuant to the terms of the exclusive license agreement. Virginia Commonwealth University On May 18, 2020 (the “VCU Effective Date”), the Company entered into an Exclusive License Agreement (the “VCU License Agreement”) with the Virginia Commonwealth University Intellectual Property Foundation (“VCU”). Pursuant to the VCU License Agreement, VCU granted the Company an exclusive, royalty bearing license to a novel peptide developed by researchers at VCU that may be used to slow the transmission of SARS-CoV-2 (the “VCU Licensed Patent”) and a non-exclusive royalty bearing, worldwide license with respect to the Licensed Technical Information Patents (as defined in the VCU License Agreement) to make, have made, use, offer to sell, sell and import the Licensed Products (as defined in the VCU License Agreement) and perform the Licensed Services (as defined in the VCU License Agreement). The VCU License Agreement shall commence on the VCU Effective Date and shall continue until the expiration of the last to expire VCU Licensed Patent unless terminated earlier pursuant to the terms of the agreement. Pursuant to the VCU License Agreement, the Company shall pay VCU: (i) an upfront license issue fee, (ii) running royalty payments at a low single digit percentage of Net Sales (as defined in the VCU License Agreement), (iii) annual maintenance fees commencing on the first anniversary of the VCU Effective Date, (iv) annual minimum payments ranging from the mid five figures to low six figures commencing on the second anniversary of the VCU Effective Date and (v) milestone payments ranging from the mid five figures to low six figures. In addition, the Company has agreed to reimburse VCU for certain patent filing and prosecution costs. During the nine months ended September 30, 2020, the Company paid the signing fee of $50,000 upon execution of the VCU License Agreement. Pursuant to the VCU License Agreement, the Company has agreed to pay VCU an annual license fee and to make annual minimum payments. On June 29, 2020, the Company entered into a Sponsored Project Agreement (the “VCU Sponsored Project Agreement”) with VCU for the development of a potential COVID-19 treatment using the license to a novel peptide granted to the Company by VCU. The VCU Sponsored Project Agreement shall terminate on January 9, 2021, unless earlier terminated pursuant to the terms thereof. Zylö Therapeutics Inc. On August 19, 2019 (the “Zylö Effective Date”), the Company entered into an exclusive sublicense agreement (the “Sublicense Agreement”) with Zylö Therapeutics, Inc. (“Zylö”) pursuant to which Zylö granted to the Company an exclusive sublicense to the Licensed Patent Rights (as defined in the Sublicense Agreement) and the Licensed Technology (as defined in the Sublicense Agreement) to, among other things, develop, make and sell the Licensed Products (as defined in the Sublicense Agreement) and to practice the Licensed Technology in the United States and Canada for any and all uses within the Field. “Field” means all therapeutic uses related to lupus in human beings, subject to the Field Expansion Rights (as defined in the Sublicense Agreement). The term of the Sublicense Agreement shall commence on the Zylö Effective Date and shall continue until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product in such country and (ii) expiration of the last to expire Valid Claim (as defined in the Sublicense Agreement) of the Licensed Patent Rights that would be infringed by the composition, use or sale of such Licensed Product in such country. Pursuant to the terms of the Sublicense Agreement, the Company and Zylö shall establish a joint development committee to plan, review, coordinate and oversee the Company’s development activities with respect to the Licensed Products in the Field. Pursuant to the Sublicense Agreement, the Company paid Zylö an upfront license fee of $50,000 and is required to pay Zylö (i) sales-based royalties at percentages which range from high single digits to low double digits, with low sales volumes being subject to lower royalty rates; and (ii) total milestone payments of up to $13.5 million. In addition, in connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 30,000 shares of Zylö’s Class B common stock for $60,000. Effective January 1, 2018, the Company adopted ASU 2016-01 concerning recognition and measurement of financial assets and financial liabilities. In adopting this new guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for its investment in Zylö.

3500000 6000 Pursuant to the terms of the Sponsored Research Agreement, GW granted the Company a non-exclusive license to certain of GW’s intellectual property. The Company has agreed to pay GW for all costs incurred in connection with the research; provided, however, such costs shall not exceed approximately $0.5 million

2500

10000

(i) $75,000 per year for the development and commercialization of the GW Licensed Product, (ii) $2,000 for license maintenance fees on the first anniversary of the Effective Date and (iii) $5,000 for license maintenance fees commencing on the second anniversary of the Effective Date and thereafter. Furthermore, the Company shall be required to pay GW a sublicense fee equal to a certain percentage of the sum of payments plus the fair market value of all other consideration of any kind received by the Company from sublicensees during each quarter as follows: a 40% sublicense fee until the first anniversary of the Effective Date, a 30% sublicense fee until the third anniversary of the Effective Date and a 20% sublicense fee after the third anniversary of the Effective Date; provided, however, such sublicense fee shall exclude certain fees paid to the Company such as certain royalties, equity investments, loan proceeds and sponsored research funding. The Company shall also pay GW milestone payments of up to an aggregate of $90,000 and sales-based royalties at a low single digit percentage, subject to certain minimum royalty requirements. In addition, during each Option Exercise Period and Renewal Period (as defined in the Research Option Agreement) the Company shall pay GW, on a quarterly basis, for all costs and expenses related to the GW Licensed Patents (the “Patent Costs”). the Company entered into a commercial evaluation sublicense and option agreement (the “Commercial Evaluation Sublicense and Option Agreement”) with the University of Maryland, Baltimore (“UMB”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”). Pursuant to the agreement, the Company paid an initial option and material access fee of $5,000 to UMB and $5,000 to Isoprene.

20000

Pursuant to the Isoprene Sublicense Agreement, the Company shall pay Isoprene, among other things, (i) a license fee, (ii) a royalty rate at a middle single digit percentage, (iii) milestone payments of up to $1,375,000 and (iv) revenue interest at a low single digit percentage based on the net revenue of covered products sold by Isoprene during the Isoprene Term.

25000

50000

585000 5000 5000 120000 P10Y 50000 upfront license fee of $50,000 and is required to pay Zylö (i) sales-based royalties at percentages which range from high single digits to low double digits, with low sales volumes being subject to lower royalty rates; and (ii) total milestone payments of up to $13.5 million. In addition, in connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 30,000 shares of Zylö’s Class B common stock for $60,000. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">153,590</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">195,605</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Isoprene Pharmaceuticals, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>University of Cincinnati</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">University of Maryland and Isoprene Pharmaceuticals, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Zylö Therapeutics, Inc.</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">231,090</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">50,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">625,605</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">70,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 153590 2500 195605 2500 30000 30000 17500 7500 35000 7500 10000 30000 365000 40000 50000

Note 4-Note Receivable Pursuant to Isoprene Sublicense Agreement dated July 30, 2020, the Company made an investment of $50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred in a private financing that results in gross proceeds of at least $5 million. “Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization Isoprene immediately prior to the conversion of the Isoprene Note. In the event a Change of Control occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Qualified Financing, the Isoprene Note may be converted into such number of shares of Isoprene’s common stock equal to the quotient obtained by dividing (i) the balance of the Isoprene Note by (ii) two times the fair market value of a share of Isoprene common stock as set for in the acquisition agreement pertaining to such Change of Control.

50000

The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred in a private financing that results in gross proceeds of at least $5 million. (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization Isoprene immediately prior to the conversion of the Isoprene Note.

Note 5-Related Party A former director of the Company, is also the Executive Chairman of Chelexa. During the nine months ended September 30, 2020, such former director received $22,500 in cash compensation for services provided as a member of the Company’s board of directors (the “Board” or “Board of Directors”). On September 30, 2020, this director resigned as a member of the Company’s Board of Directors. A former director of the Company, is also the Chief Executive Officer, Principal Accounting and Financial Officer and a member of the board of directors of AIkido Pharma Inc. (formerly known as Spherix Incorporated). During the nine months ended September 30, 2020, such former director received $8,700 in cash compensation for services provided as a member of the Company’s Board of Directors. On April 15, 2020, this director resigned as a member of the Company’s Board of Directors and its committees. Options issued to him expired on July 15, 2020, which is further described in Note of 8 these financial statements.  During the nine months ended September 30, 2020, the Company issued an aggregate of 7,350 shares of the Company’s common stock to members of the Company’s Board for services rendered.

22500

8700

7350

Note 6-Fair Value of Financial Assets FASB ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%; text-align: justify">Level 1:</td> <td style="width: 93%; text-align: justify">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Level 2:</td> <td style="text-align: justify">Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Level 3:</td> <td style="text-align: justify">Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</td></tr> </table> In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. The Company’s financial instruments include cash, marketable securities and accounts payable. The fair value of these financial instruments approximates their carrying value due to the short-term nature. With respect to the Company’s investment in a joint venture, the fair value of this investment approximates its carrying value due to the minimal transaction activity within this joint venture. The following table presents the Company’s assets and liabilities that are measured at fair value at September 30, 2020 and December 31, 2019: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measured at September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted prices in active markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant unobservable inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 18px">Marketable securities - mutual funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,290,022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,290,022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured at December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted prices in active markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant unobservable inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 18px">Marketable securities - mutual funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">803,664</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">803,664</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td></tr> </table> Fair Value Measurements on a Non-Recurring Basis The Company measures the fair value of certain assets on a non-recurring basis, generally quarterly, annually, or when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. These assets include the investment in joint venture accounted for using the equity method and investment in Zylö for using cost method. When the Company determines that the carrying value of these assets may not be recoverable, the Company records the assets at fair value with the loss recognized in the condensed consolidated statements of operations and comprehensive loss. In such cases, the Company measures the fair value of these assets using the techniques discussed above under the Level 3 category.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measured at September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted prices in active markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant unobservable inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 18px">Marketable securities - mutual funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,290,022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,290,022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured at December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total at December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted prices in active markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant other observable inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant unobservable inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Assets</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 18px">Marketable securities - mutual funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">803,664</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">803,664</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">      -</td><td style="width: 1%; text-align: left"> </td></tr> </table>

1290022

803664

Note 7-Investment in HaloVax On March 23, 2020, the Company entered into a Development and Royalty Agreement (the “Development and Royalty Agreement”) with Voltron Therapeutics, Inc. (“Voltron”) to form a joint venture entity named HaloVax, LLC (“HaloVax”) to jointly develop potential product candidates for the prevention of COVID-19  based upon certain technology that had been exclusively licensed by Voltron from The General Hospital Corporation (d/b/a Massachusetts General Hospital). Pursuant to the Development and Royalty Agreement, the Company is entitled to receive sales-based royalties. In addition, pursuant to the terms of the Development and Royalty Agreement, on March 23, 2020, the Company and HaloVax entered into a Membership Interest Purchase Agreement  pursuant to which the Company purchased 5% of HaloVax’s outstanding membership interests for $250,000 on March 27, 2020 (the “Initial Closing Date”) and shall have the option to purchase up to an additional 25% of HaloVax’s membership interests (for $3,000,000 (inclusive of the $250,000)), which option shall expire 30 days after the Initial Closing Date. On May 28, 2020, the Company entered into a membership interest purchase agreement to purchase 1% of HaloVax’s outstanding membership interest for a purchase price of $100,000. As such, the Company accounts for those investments under the equity method. There was no significant change in HaloVax’s operations from March 23, 2020 to September 30, 2020. the Company and HaloVax entered into a Membership Interest Purchase Agreement pursuant to which the Company purchased 5% of HaloVax’s outstanding membership interests for $250,000 on March 27, 2020 (the “Initial Closing Date”) and shall have the option to purchase up to an additional 25% of HaloVax’s membership interests (for $3,000,000 (inclusive of the $250,000)), which option shall expire 30 days after the Initial Closing Date. the Company entered into a membership interest purchase agreement to purchase 1% of HaloVax’s outstanding membership interest for a purchase price of $100,000.

Note 8-Stockholders’ Equity  Common Stock On January 17, 2020, pursuant to the termination and general release agreement between the Company and FON Consulting LLC, 15,000 of the shares originally issued to FON Consulting LLC were cancelled. On February 5, 2020, the Company issued 12,500 shares of common stock upon exercise of warrants issued to an investor on January 19, 2018, which resulted in gross proceeds of $12,500. On March 6, 2020, the Company issued 25,000 shares of common stock upon exercise of the warrants issued to an investor on December 13, 2017, which resulted in gross proceeds of $25,000. On April 15, 2020, the Company issued each of two directors 3,333 shares of the Company’s common stock pursuant to the Company’s 2018 Equity Incentive Plan which shares vest in 36 equal monthly installments with the first installment vesting on the date of grant. On May 18, 2020, the Company issued 6,250 shares of common stock upon exercise of warrants issued to an investor on February 2, 2018, which resulted in gross proceeds of $6,250. On June 3, 2020, the Company issued 12,500 shares of common stock upon exercise of warrants issued to an investor on November 20, 2017, which resulted in gross proceeds of $12,500. During the nine months ended September 30, 2020, the Company issued an aggregate of 7,350 shares of the Company’s common stock to members of the Company’s Board for services rendered. Public Offering of Securities On March 24, 2020 (the “UA Effective Date”), the Company entered into an underwriting agreement with Laidlaw & Company (UK) Ltd. (“Laidlaw”), the representative of the underwriters, relating to a best efforts underwritten public offering of 1,449,275 shares (the “Shares”) of the Company’s common stock at a public offering price of $3.45 per Share. The Company received net proceeds of approximately $4.2 million, after deducting the underwriting discount and offering expenses. In connection with the offering, the Company issued Laidlaw warrants to purchase up to 72,464 shares of the Company’s common stock, representing 5% of the aggregate number of Shares sold in the offering. The warrants will be exercisable for a period of five years from the UA Effective Date at a price per share equal to $4.14 (120% of the public offering price per Share) and are exercisable on a “cashless” basis. The Company has reimbursed Laidlaw for certain of its out-of-pocket expenses incurred in connection with the offering. On May 21, 2020 (the “Benchmark Effective Date”), the Company entered into an underwriting agreement with The Benchmark Company, LLC (“Benchmark”), as representative of the several underwriters, relating to the public offering of 1,818,182 shares of the Company’s common stock at a price to the public of $2.75 per share. The Company received net proceeds of approximately $4.5 million, after deducting the underwriting discount and offering expenses. In connection with the offering, the Company issued Benchmark warrants to purchase 90,909 shares of the Company’s common stock. The warrants are exercisable for a period of five years commencing six months from the Benchmark Effective Date at a price per share equal to $2.75 and are exercisable on a “cashless” basis. Restricted Stock Awards On April 15, 2020, the Company issued each of two directors 3,333 shares of the Company’s common stock pursuant to the Company’s 2018 Equity Incentive Plan which shares vest in 36 equal monthly installments with the first installment vesting on the date of grant. A summary of the Company’s restricted stock grants under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) during the nine months ended September 30, 2020 is as follows:  <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Day Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Nonvested at December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 18px">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18px">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,350</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Nonvested at September 30, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12,516</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.47</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> As of September 30, 2020, the Company had approximately $12,000 of unrecognized stock-based compensation expense which was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards is approximately 1.47 years at September 30, 2020. Stock Options On July 8, 2020, the compensation committee of the Board of Directors approved the issuance of ten-year options to purchase up to 49,212 shares of the Company’s common stock at an exercise price of $2.54 per share pursuant to the 2018 Plan to an advisor for services to be rendered. The aggregate grant date fair value of these options was approximately $0.1 million. The stock options vested in full upon grant. On July 15, 2020, an option to purchase up to 35,000 shares of the Company’s common stock originally issued on December 24, 2019 to a former board member expired after such board member’s resignation from the board effective as of on April 15, 2020. On July 21, 2020, the Company’s Board of Directors approved the issuance of ten-year options to purchase an aggregate of 200,000 shares of the Company’s common stock at an exercise price of $3.05 per share pursuant to the 2018 Plan to directors and certain officers of the Company in consideration for services rendered. The aggregate grant date fair value of these options was approximately $0.5 million. The stock options vested in full upon grant. A summary of option activity under the Company’s stock option plan for nine months ended September 30, 2020 is presented below:  <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">525,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">457,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.4</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9px">Employee options issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9px">Non - employee options issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9px">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">739,212</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.52</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Options vested and exercisable</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">739,212</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4.52</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9.0</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Warrants Pursuant to the Patent License Agreement between the Company and GW dated February 1, 2020, on February 27, 2020 (the “February Warrant Date of Issuance”), the Company issued GW warrants (the “February Warrants”) to purchase up to 22,988 shares of the Company’s common stock at an exercise price of $4.35 per share. The February Warrants vest as follows: 20% upon the February Warrant Date of Issuance and the balance, or 80% of the February Warrants shall vest in four equal annual installments of 20% on each anniversary of the February Warrant Date of Issuance. Pursuant to the GW Patent License Agreement between the Company and GW dated August 7, 2020, on August 10, 2020 (the “August Warrant Date of Issuance”), the Company issued GW ten year warrants (the “August Warrants”) to purchase up to 72,463 shares of the Company’s common stock at an exercise price of $2.76 per share. The August Warrants vest as follows: 20% upon the August Warrant Date of Issuance and the balance, or 80% of the August Warrants shall vest in four equal annual installments of 20% on each anniversary of the August Warrant Date of Issuance. In connection with the public offering of securities discussed above, the Company granted to Laidlaw and Benchmark warrants to purchase up to 72,464 and 90,909 shares of the Company’s common stock, respectively. A summary of warrant activity for the nine months ended September 30, 2020 is as follows:  <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,692</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.91</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,725,745</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>   Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9px">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Outstanding as of September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,235,266</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.07</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">696,334</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of September 30, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,158,906</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.07</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">696,334</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3.7</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The Company has determined that the warrants should be accounted as a component of stockholders’ equity. Stock Based Compensation Stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019 was as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Employee stock option awards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">487,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">487,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,182</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-employee stock option awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,499</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-employee restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204,550</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-employee stock warrant awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,590</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,605</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,605</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 18px"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">661,132</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">206,760</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">700,909</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">496,836</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Employee related stock-based compensation is recognized as “compensation and related expenses” and non-employee related stock-based compensation is recognized as “professional fees” or “research and development - licenses acquired” in the condensed statements of operations and comprehensive loss.

15000

12500

25000

3333 6250

6250

12500

7350

1449275 3.45

4200000

72464 the Company’s common stock, representing 5% of the aggregate number of Shares sold in the offering. The warrants will be exercisable for a period of five years from the UA Effective Date at a price per share equal to $4.14 (120% of the public offering price per Share) and are exercisable on a “cashless” basis. The Company has reimbursed Laidlaw for certain of its out-of-pocket expenses incurred in connection with the offering. 1818182 2.75

4500000

90909

P5Y

2.75

3333

12000

P1Y171D

49212

2.54

100000 35000 200000

3.05

500000 22988

4.35

The February Warrants vest as follows: 20% upon the February Warrant Date of Issuance and the balance, or 80% of the February Warrants shall vest in four equal annual installments of 20% on each anniversary of the February Warrant Date of Issuance. 72463

2.76

The August Warrants vest as follows: 20% upon the August Warrant Date of Issuance and the balance, or 80% of the August Warrants shall vest in four equal annual installments of 20% on each anniversary of the August Warrant Date of Issuance. 72464 90909

13200

0.25

6666

3.00

7350

0.66

12516

1.47

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">525,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">457,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.4</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9px">Employee options issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9px">Non - employee options issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9px">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">739,212</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.52</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Options vested and exercisable</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">739,212</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4.52</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9.0</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

525000

5.32

457250

P9Y146D

200000

3.05

P9Y292D 49212 2.54 P9Y292D

35000

739212

4.52

P9Y

739212

4.52

P9Y

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,692</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.91</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,725,745</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>   Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9px">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Outstanding as of September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,235,266</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.07</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">696,334</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of September 30, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,158,906</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.07</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">696,334</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3.7</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

1032692

2.91

3725745

P4Y73D

258824 3.28 P5Y73D -56250 1.00 1235266

3.07

696334 P3Y255D

1158906

3.07

696334

P3Y255D

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Employee stock option awards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">487,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">487,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,182</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-employee stock option awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,499</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-employee restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204,550</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-employee stock warrant awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,590</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,605</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,605</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 18px"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">661,132</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">206,760</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">700,909</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">496,836</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

487963

199182

100104

4475

2210

12237

8499

204550

68590

100605

84605

661132

206760

700909

496836

Note 9-Commitments and contingencies Office lease The Company leases office space for approximately $2,000 a month. Rent expense for the nine months ended September 30, 2020 and 2019 was approximately $19,000 and $24,000, respectively. Litigation From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.

2000

19000

24000

Note 10-Risk and Uncertainties The outbreak of the novel Coronavirus (COVID-19) has evolved into a global pandemic. The Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts the Company’s business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its impact, among others. As a result of the continuing spread of the Coronavirus, certain aspects of the Company’s business operations have been delayed, and the Company may be subject to additional delays or interruptions. Specifically, as a result of the shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development activities of certain of the Company’s partners have been affected, resulting in delays to the Company’s clinical trials, and the Company can provide no assurance as to when such trials will resume at this time or the revised timeline to complete trials once resumed. Furthermore, site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If the Coronavirus continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and the Company may be unable to conduct its clinical trials. Further, if the spread of the Coronavirus pandemic continues and our operations are adversely impacted, the Company risks a delay, default and/or nonperformance under existing agreements which may increase our costs. These cost increases may not be fully recoverable or adequately covered by insurance. Infections and deaths related to the pandemic may disrupt the United States’ healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval with respect to, the Company’s clinical trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of the Company’s clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the Company’s product candidates. The Company currently utilizes third parties to, among other things, manufacture raw materials. If any third-party party in the supply chain for materials used in the production of the Company’s product candidates are adversely impacted by restrictions resulting from the Coronavirus outbreak, the Company’s supply chain may be disrupted, limiting the Company’s ability to manufacture its product candidates for its clinical trials and research and development operations. The spread of the Coronavirus, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on the Company’s business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the Coronavirus could materially and adversely affect the Company’s business and the value of its common stock. The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s operations, and the Company will continue to monitor the situation closely.

Note 11-Subsequent events The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements other than disclosed.

EX-101.SCH 7 hoth-20200930.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Alternate 0 link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business Operations link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - License Agreements link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Note Receivable link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Related Party link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Fair Value of Financial Assets link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Investment in HaloVax link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Risk and Uncertainties link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - License Agreements (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Fair Value of Financial Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Significant Accounting Policies (Details) - Schedule of cash and restricted cash total as presented in the condensed statements of cash flows link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Significant Accounting Policies (Details) - Schedule of anti-dilutive impact on net loss link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - License Agreements (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - License Agreements (Details) - Schedule of research and development expenses for licenses acquired link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Note Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Fair Value of Financial Assets (Details) - Schedule of assets and liabilities measured at fair value link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Investment in HaloVax (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock awards activities under the Company's 2018 Equity Incentive Plan link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option plan link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Stockholders' Equity (Details) - Schedule of warrant activity link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Stockholders' Equity (Details) - Schedule of stock-based compensation expense link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 hoth-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 hoth-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 hoth-20200930_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] Total current assets Total assets Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Total liabilities and stockholders’ equity Income Statement [Abstract] Total operating expenses Loss from operations Total other income Net loss Net loss Total comprehensive loss Statement of Stockholders' Equity [Abstract] Balance Balance Balance (in Shares) Balance (in Shares) Equity Components [Axis] Cumulative Effect, Period of Adoption [Axis] Statement of Cash Flows [Abstract] Net cash used in investing activities Net cash provided by financing activities Net increase in cash Cash and restricted cash, beginning of period Cash and restricted cash, end of period Accounting Policies [Abstract] Schedule of cash and restricted cash total as presented in the condensed statements of cash flows [Abstract] Total cash and restricted cash Schedule of anti-dilutive impact on net loss [Abstract] Antidilutive Securities [Axis] Retirement Benefits [Abstract] Schedule of research and development expenses for licenses acquired [Abstract] Related Party [Axis] Premiums Receivable Disclosure [Abstract] Related Party Transactions [Abstract] Fair Value Disclosures [Abstract] Schedule of assets and liabilities measured at fair value [Abstract] Fair Value Hierarchy and NAV [Axis] Investment In Halovax [Abstract] Stockholders' Equity Note [Abstract] Schedule of restricted stock awards activities under the Company's 2018 Equity Incentive Plan [Abstract] Number of Units, Nonvested Beginning Balance Number of Units, Nonvested Ending Balance Weighted Average Grant Day Fair Value, Nonvested Beginning balance Weighted Average Grant Day Fair Value, Nonvested Ending balance Schedule of stock option plan [Abstract] Number of Shares, Outstanding Beginning Balance Number of Shares, Ending Balance Number of Warrants, Outstanding Weighted Average Exercise Price, Outstanding Beginning Balance Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Outstanding (in Dollars per share) Total Intrinsic Value, Outstanding Beginning Balance Total Intrinsic Value, Ending Balance Award Type [Axis] Schedule of warrant activity [Abstract] Schedule of stock-based compensation expense [Abstract] Sale of Stock [Axis] Commitments and Contingencies Disclosure [Abstract] Risks and Uncertainties [Abstract] Subsequent Events [Abstract] Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Filer Category Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Registrant Name Entity Shell Company Entity Small Business ASSETS Current assets Cash Marketable equity securities, at fair value Marketable securities - mutual funds Prepaid expenses Deferred offering cost Note receivable Property and equipment, net Investment in joint venture Restricted cash LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Accrued expenses Accrued license fee - current portion Accrued license fee Commitments and contingencies Stockholders’ equity Preferred stock value Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, $0.0001 par value, 75,000,000 shares authorized, 13,435,901 and 10,119,844 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in-capital Accumulated deficit Accumulated other comprehensive loss Operating costs and expenses Research and development Research and development - licenses acquired (including stock-based compensation) Total Compensation and related expenses (including stock-based compensation) Professional fees (including stock-based compensation) Rent Other expenses Other income Other income, net Weighted average number of common shares outstanding, basic and diluted (in Shares) Net loss per share, basic and diluted (in Dollars per share) Other comprehensive loss Foreign currency translation adjustment Stock-based compensation Stock-based compensation (in Shares) Cumulative translation adjustment Common stock upon exercise of warrants issued (in Dollars) Issuance common stock and warrants, net of offering cost Issuance common stock and warrants, net of offering cost (in Shares) Issuance common stock and warrants net of offering cost Issuance common stock in the IPO, net of offering cost Issuance common stock in the IPO, net of offering cost (in Shares) Issuance common stock in the IPO net of offering cost Cancellation of common stock Cancellation of common stock (in Shares) Warrant exercise Warrant exercise (in Shares) Conversion of preferred stock to common stock upon completion of the IPO Conversion of preferred stock to common stock upon completion of the IPO (in Shares) Cashless warrant exercise Cashless warrant exercise (in Shares) Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Research and development-acquired license, expensed Stock-based compensation Changes in assets and liabilities: Accounts payable Net cash used in operating activities Cash flows from investing activities Purchase of investments in joint venture Sale of marketable securities Cash flows from financing activities Proceeds from issuance of common stock in the IPO, net of offering cost Proceeds from issuance common stock and warrants, net of offering cost Proceeds from issuance common stock, net of offering cost Proceeds from exercise of warrants Effect of exchange rate changes on cash and cash equivalents Non-cash investing and financing activities Conversion of preferred stock to common stock upon completion of the IPO Cancellation and retirement of common stock Cashless warrant exercise Realized gain on marketable securities Unrealized gain on marketable securities Prepaid expenses Purchase of research and development licenses Purchase of marketable securities Purchase of convertible promissory note in Isoprene Series A Convertible Preferred Stock Common Stock Common Stock [Member] Additional Paid-in Capital Accumulated Deficit Cumulative Translation Adjustment Convertible Preferred Stock Organization and description of business operations Significant accounting policies Schedule of cash and restricted cash total as presented in the condensed statements of cash flows Cash Restricted cash Schedule of anti-dilutive impact on net loss Total License agreements Schedule of research and development expenses for licenses acquired Note Receivable Related Party Fair Value of Financial Assets Schedule of assets and liabilities measured at fair value Assets Assets Investment in HaloVax Stockholders' Equity Schedule of stock option plan Number of Units, Granted Weighted Average Grant Day Fair Value, Granted Weighted Average Grant Day Fair Value, Vested Schedule of stock option plan EX-101.PRE 11 hoth-20200930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 09, 2020
Document Information Line Items
Entity Registrant Name	Hoth Therapeutics, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		13,437,473
Amendment Flag	false
Entity Central Index Key	0001711786
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	001-38803
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash	$ 4,120,565	$ 1,690,866
Marketable equity securities, at fair value	1,290,022	803,664
Prepaid expenses	79,563	110,072
Deferred offering cost		30,484
Total current assets	5,490,150	2,635,086
Note receivable	50,000
Property and equipment, net	124	1,043
Investment in joint venture	410,000
Restricted cash		200,000
Total assets	5,950,274	2,836,129
Current liabilities
Accounts payable	22,919	403,885
Accrued expenses	132,452	36,236
Accrued license fee - current portion	132,500
Total current liabilities	287,871	440,121
Accrued license fee	285,000
Total liabilities	572,871	440,121
Commitments and contingencies
Stockholders’ equity
Preferred stock value
Common stock, $0.0001 par value, 75,000,000 shares authorized, 13,435,901 and 10,119,844 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	1,343	1,012
Additional paid-in-capital	24,036,222	14,610,638
Accumulated deficit	(18,656,671)	(12,215,642)
Accumulated other comprehensive loss	(3,491)
Total stockholders’ equity	5,377,403	2,396,008
Total liabilities and stockholders’ equity	5,950,274	2,836,129
Series A Convertible Preferred Stock
Stockholders’ equity
Preferred stock value

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	13,435,901	10,119,844
Common stock, shares outstanding	13,435,901	10,119,844
Series A Convertible Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,897,250	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating costs and expenses
Research and development	$ 517,839	$ 490,266	$ 2,092,763	$ 1,013,950
Research and development - licenses acquired (including stock-based compensation)	231,090	50,000	625,605	70,000
Compensation and related expenses (including stock-based compensation)	667,694	336,838	1,225,090	791,773
Professional fees (including stock-based compensation)	620,620	643,311	2,176,683	1,481,675
Rent	7,525	8,354	18,533	23,617
Other expenses	122,063	171,675	360,424	416,380
Total operating expenses	2,166,831	1,700,444	6,499,098	3,797,395
Loss from operations	(2,166,831)	(1,700,444)	(6,499,098)	(3,797,395)
Other income
Other income, net	49,908	4,412	58,069	4,412
Total other income	49,908	4,412	58,069	4,412
Net loss	$ (2,116,923)	$ (1,696,032)	$ (6,441,029)	$ (3,792,983)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	13,434,884	9,886,759	12,001,987	8,842,905
Net loss per share, basic and diluted (in Dollars per share)	$ (0.16)	$ (0.17)	$ (0.54)	$ (0.43)
Net loss	$ (2,116,923)	$ (1,696,032)	$ (6,441,029)	$ (3,792,983)
Other comprehensive loss
Foreign currency translation adjustment	(2,829)		(3,491)
Total comprehensive loss	$ (2,119,752)	$ (1,696,032)	$ (6,444,520)	$ (3,792,983)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Cumulative Translation Adjustment	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018		$ 310	$ 507	$ 4,665,154	$ (4,511,006)	$ 154,965
Balance (in Shares) at Dec. 31, 2018		3,102,480	5,071,400
Conversion of preferred stock to common stock upon completion of the IPO		$ (310)	$ 310
Conversion of preferred stock to common stock upon completion of the IPO (in Shares)		(3,102,480)	3,102,480
Issuance common stock and warrants, net of offering cost			$ 41	1,610,089		1,610,130
Issuance common stock and warrants, net of offering cost (in Shares)			407,424
Cashless warrant exercise			$ 22	(22)
Cashless warrant exercise (in Shares)			223,877
Issuance common stock in the IPO, net of offering cost			$ 125	5,840,042		5,840,167
Issuance common stock in the IPO, net of offering cost (in Shares)			1,250,000
Warrant exercise			$ 2	161		163
Warrant exercise (in Shares)			16,333
Stock-based compensation			$ 5	496,831		496,836
Stock-based compensation (in Shares)			46,248
Net loss					(3,792,983)	(3,792,983)
Balance at Sep. 30, 2019			$ 1,012	12,612,255	(8,303,989)	4,309,278
Balance (in Shares) at Sep. 30, 2019			10,117,762
Balance at Jun. 30, 2019			$ 967	10,795,410	(6,607,957)	4,188,420
Balance (in Shares) at Jun. 30, 2019			9,668,256
Issuance common stock and warrants, net of offering cost			$ 41	1,610,089		1,610,130
Issuance common stock and warrants, net of offering cost (in Shares)			407,424
Stock-based compensation			$ 4	206,756		206,760
Stock-based compensation (in Shares)			42,082
Net loss					(1,696,032)	(1,696,032)
Balance at Sep. 30, 2019			$ 1,012	12,612,255	(8,303,989)	4,309,278
Balance (in Shares) at Sep. 30, 2019			10,117,762
Balance at Dec. 31, 2019			$ 1,012	14,610,638	(12,215,642)	2,396,008
Balance (in Shares) at Dec. 31, 2019			10,119,844
Issuance common stock and warrants, net of offering cost			$ 145	4,193,611		4,193,756
Issuance common stock and warrants, net of offering cost (in Shares)			1,449,275
Issuance common stock in the IPO, net of offering cost			$ 182	4,474,818		4,475,000
Issuance common stock in the IPO, net of offering cost (in Shares)			1,818,182
Cancellation of common stock			$ (2)	2
Cancellation of common stock (in Shares)			(15,000)
Warrant exercise			$ 6	56,244		56,250
Warrant exercise (in Shares)			56,250
Stock-based compensation				700,909		700,909
Stock-based compensation (in Shares)			7,350
Cumulative translation adjustment	(3,491)					(3,491)
Net loss					(6,441,029)	(6,441,029)
Balance at Sep. 30, 2020	(3,491)		$ 1,343	24,036,222	(18,656,671)	5,377,403
Balance (in Shares) at Sep. 30, 2020			13,435,901
Balance at Jun. 30, 2020	(662)		$ 1,343	23,375,090	(16,539,748)	6,836,023
Balance (in Shares) at Jun. 30, 2020			13,433,267
Stock-based compensation				661,132		661,132
Stock-based compensation (in Shares)			2,634
Cumulative translation adjustment	(2,829)					(2,829)
Net loss					(2,116,923)	(2,116,923)
Balance at Sep. 30, 2020	$ (3,491)		$ 1,343	$ 24,036,222	$ (18,656,671)	$ 5,377,403
Balance (in Shares) at Sep. 30, 2020			13,435,901

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2020 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance common stock and warrants net of offering cost	$ 806,243
Issuance common stock in the IPO net of offering cost	$ 525,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (6,441,029)	$ (3,792,983)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	919	916
Research and development-acquired license, expensed	525,000	70,000
Stock-based compensation	700,909	496,836
Realized gain on marketable securities	11,060
Unrealized gain on marketable securities	(49,024)	(4,398)
Changes in assets and liabilities:
Prepaid expenses	30,509	(101,540)
Accounts payable	(254,266)	(116,967)
Net cash used in operating activities	(5,475,922)	(3,448,136)
Cash flows from investing activities
Purchase of investments in joint venture	(410,000)
Purchase of research and development licenses	(107,500)	(70,000)
Purchase of marketable securities	(1,500,000)	(800,000)
Purchase of convertible promissory note in Isoprene	(50,000)
Sale of marketable securities	1,051,606
Net cash used in investing activities	(1,015,894)	(870,000)
Cash flows from financing activities
Proceeds from issuance of common stock in the IPO, net of offering cost		5,840,167
Proceeds from issuance common stock and warrants, net of offering cost	4,193,756	1,610,130
Proceeds from issuance common stock, net of offering cost	4,475,000
Proceeds from exercise of warrants	56,250	163
Net cash provided by financing activities	8,725,006	7,450,460
Effect of exchange rate changes on cash and cash equivalents	(3,491)
Net increase in cash	2,229,699	3,132,324
Cash and restricted cash, beginning of period	1,890,866	282,621
Cash and restricted cash, end of period	4,120,565	3,414,945
Non-cash investing and financing activities
Conversion of preferred stock to common stock upon completion of the IPO		310
Cancellation and retirement of common stock	2
Cashless warrant exercise		$ 22

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization and Description of Business Operations

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Organization and description of business operations

Note 1-Organization and description of business operations

Liquidity and capital resources

XML 20 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Significant accounting policies

Note 2-Significant accounting policies

Basis of Presentation and Principles of Consolidation

Use of estimates

Significant Accounting Policies

Restricted Cash

	September 30, 2020		September 30, 2019		December 31, 2019
Cash	$	4,120,565	$	3,214,945	$	1,690,866
Restricted cash		-		200,000		200,000
Total cash and restricted cash	$	4,120,565	$	3,414,945	$	1,890,866

Net loss per share

	As of September 30,
Potentially dilutive securities	2020		2019
Warrants		1,235,266		1,032,692
Options		739,212		-
Non-vested restricted stock units		12,516		15,282
Total		1,986,994		1,047,974

Investment in joint venture

Recent accounting pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

License Agreements

9 Months Ended

Sep. 30, 2020

Retirement Benefits [Abstract]

License agreements

Note 3-License agreements

The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during three and nine months ended September 30, 2020 and 2019:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
The George Washington University	$	153,590	$	2,500	$	195,605	$	2,500
Isoprene Pharmaceuticals, Inc.		30,000		-		30,000		-
University of Cincinnati		17,500		7,500		35,000		7,500
University of Maryland and Isoprene Pharmaceuticals, Inc.		-		-		-		10,000
Virginia Commonwealth University		30,000		-		365,000		-
Zylö Therapeutics, Inc.		-		40,000		-		50,000
	$	231,090	$	50,000	$	625,605	$	70,000

Chelexa Biosciences, Inc. and the University of Cincinnati

The George Washington University

University of Maryland and Isoprene Pharmaceuticals, Inc.

North Carolina State University

University of Cincinnati

Virginia Commonwealth University

Zylö Therapeutics Inc.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note Receivable

9 Months Ended

Sep. 30, 2020

Premiums Receivable Disclosure [Abstract]

Note Receivable

Note 4-Note Receivable

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party

9 Months Ended

Sep. 30, 2020

Related Party

Note 5-Related Party

During the nine months ended September 30, 2020, the Company issued an aggregate of 7,350 shares of the Company’s common stock to members of the Company’s Board for services rendered.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Assets

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value of Financial Assets

Note 6-Fair Value of Financial Assets

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:	Quoted prices in active markets for identical assets or liabilities.

Level 2:	Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:	Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

The following table presents the Company’s assets and liabilities that are measured at fair value at September 30, 2020 and December 31, 2019:

	Fair value measured at September 30, 2020
	Total at September 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2020		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities - mutual funds	$	1,290,022	$	1,290,022	$	-	$	-

	Fair value measured at December 31, 2019
	Total at December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2019		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities - mutual funds	$	803,664	$	803,664	$	-	$	-

Fair Value Measurements on a Non-Recurring Basis

XML 25 R14.htm IDEA: XBRL DOCUMENT

Investment in HaloVax

9 Months Ended

Sep. 30, 2020

Investment In Halovax [Abstract]

Investment in HaloVax

Note 7-Investment in HaloVax

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Note 8-Stockholders’ Equity

Common Stock

On January 17, 2020, pursuant to the termination and general release agreement between the Company and FON Consulting LLC, 15,000 of the shares originally issued to FON Consulting LLC were cancelled.

On February 5, 2020, the Company issued 12,500 shares of common stock upon exercise of warrants issued to an investor on January 19, 2018, which resulted in gross proceeds of $12,500.

On March 6, 2020, the Company issued 25,000 shares of common stock upon exercise of the warrants issued to an investor on December 13, 2017, which resulted in gross proceeds of $25,000.

On May 18, 2020, the Company issued 6,250 shares of common stock upon exercise of warrants issued to an investor on February 2, 2018, which resulted in gross proceeds of $6,250.

On June 3, 2020, the Company issued 12,500 shares of common stock upon exercise of warrants issued to an investor on November 20, 2017, which resulted in gross proceeds of $12,500.

During the nine months ended September 30, 2020, the Company issued an aggregate of 7,350 shares of the Company’s common stock to members of the Company’s Board for services rendered.

Public Offering of Securities

Restricted Stock Awards

A summary of the Company’s restricted stock grants under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) during the nine months ended September 30, 2020 is as follows:

	Number of Units			Weighted Average Grant Day Fair Value
Nonvested at December 31, 2019		13,200		$	0.25
Granted		6,666			3.00
Vested		(7,350	)		0.66
Nonvested at September 30, 2020		12,516		$	1.47

Stock Options

A summary of option activity under the Company’s stock option plan for nine months ended September 30, 2020 is presented below:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2019		525,000		$	5.32	$	457,250		9.4
Employee options issued		200,000			3.05		-		9.8
Non - employee options issued		49,212			2.54		-		9.8
Forfeited		(35,000	)		-		-		-
Outstanding as of September 30, 2020		739,212		$	4.52	$	-		9.0
Options vested and exercisable		739,212		$	4.52	$	-		9.0

Warrants

A summary of warrant activity for the nine months ended September 30, 2020 is as follows:

	Number of Warrants			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2019		1,032,692		$	2.91	$	3,725,745		4.2
Issued		258,824			3.28		-		5.2
Exercised		(56,250	)		1.00		-		-
Outstanding as of September 30, 2020		1,235,266		$	3.07	$	696,334		3.7
Warrants exercisable as of September 30, 2020		1,158,906		$	3.07	$	696,334		3.7

The Company has determined that the warrants should be accounted as a component of stockholders’ equity.

Stock Based Compensation

Stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019 was as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Employee stock option awards	$	487,963	$	-	$	487,963	$	199,182
Non-employee stock option awards		100,104		-		100,104		-
Employee restricted stock awards		4,475		2,210		12,237		8,499
Non-employee restricted stock awards		-		204,550		-		204,550
Non-employee stock warrant awards		68,590		-		100,605		84,605
	$	661,132	$	206,760	$	700,909	$	496,836

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 9-Commitments and contingencies

Office lease

The Company leases office space for approximately $2,000 a month. Rent expense for the nine months ended September 30, 2020 and 2019 was approximately $19,000 and $24,000, respectively.

Litigation

XML 28 R17.htm IDEA: XBRL DOCUMENT

Risk and Uncertainties

9 Months Ended

Sep. 30, 2020

Risks and Uncertainties [Abstract]

Risk and Uncertainties

Note 10-Risk and Uncertainties

XML 29 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent events

Note 11-Subsequent events

XML 30 R19.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

Use of estimates

Use of estimates

Significant Accounting Policies

Significant Accounting Policies

Restricted Cash

Restricted Cash

	September 30, 2020		September 30, 2019		December 31, 2019
Cash	$	4,120,565	$	3,214,945	$	1,690,866
Restricted cash		-		200,000		200,000
Total cash and restricted cash	$	4,120,565	$	3,414,945	$	1,890,866

Net loss per share

Net loss per share

	As of September 30,
Potentially dilutive securities	2020		2019
Warrants		1,235,266		1,032,692
Options		739,212		-
Non-vested restricted stock units		12,516		15,282
Total		1,986,994		1,047,974

Investment in joint venture

Investment in joint venture

Recent accounting pronouncements

Recent accounting pronouncements

XML 31 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of cash and restricted cash total as presented in the condensed statements of cash flows

	September 30, 2020		September 30, 2019		December 31, 2019
Cash	$	4,120,565	$	3,214,945	$	1,690,866
Restricted cash		-		200,000		200,000
Total cash and restricted cash	$	4,120,565	$	3,414,945	$	1,890,866

Schedule of anti-dilutive impact on net loss

	As of September 30,
Potentially dilutive securities	2020		2019
Warrants		1,235,266		1,032,692
Options		739,212		-
Non-vested restricted stock units		12,516		15,282
Total		1,986,994		1,047,974

XML 32 R21.htm IDEA: XBRL DOCUMENT

License Agreements (Tables)

9 Months Ended

Sep. 30, 2020

Retirement Benefits [Abstract]

Schedule of research and development expenses for licenses acquired

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
The George Washington University	$	153,590	$	2,500	$	195,605	$	2,500
Isoprene Pharmaceuticals, Inc.		30,000		-		30,000		-
University of Cincinnati		17,500		7,500		35,000		7,500
University of Maryland and Isoprene Pharmaceuticals, Inc.		-		-		-		10,000
Virginia Commonwealth University		30,000		-		365,000		-
Zylö Therapeutics, Inc.		-		40,000		-		50,000
	$	231,090	$	50,000	$	625,605	$	70,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Assets (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value

	Fair value measured at September 30, 2020
	Total at September 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2020		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities - mutual funds	$	1,290,022	$	1,290,022	$	-	$	-

	Fair value measured at December 31, 2019
	Total at December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2019		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities - mutual funds	$	803,664	$	803,664	$	-	$	-

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Schedule of stock option plan

	Number of Units			Weighted Average Grant Day Fair Value
Nonvested at December 31, 2019		13,200		$	0.25
Granted		6,666			3.00
Vested		(7,350	)		0.66
Nonvested at September 30, 2020		12,516		$	1.47

Schedule of stock option plan

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2019		525,000		$	5.32	$	457,250		9.4
Employee options issued		200,000			3.05		-		9.8
Non - employee options issued		49,212			2.54		-		9.8
Forfeited		(35,000	)		-		-		-
Outstanding as of September 30, 2020		739,212		$	4.52	$	-		9.0
Options vested and exercisable		739,212		$	4.52	$	-		9.0

Schedule of warrant activity

	Number of Warrants			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2019		1,032,692		$	2.91	$	3,725,745		4.2
Issued		258,824			3.28		-		5.2
Exercised		(56,250	)		1.00		-		-
Outstanding as of September 30, 2020		1,235,266		$	3.07	$	696,334		3.7
Warrants exercisable as of September 30, 2020		1,158,906		$	3.07	$	696,334		3.7

Schedule of stock-based compensation expense

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Employee stock option awards	$	487,963	$	-	$	487,963	$	199,182
Non-employee stock option awards		100,104		-		100,104		-
Employee restricted stock awards		4,475		2,210		12,237		8,499
Non-employee restricted stock awards		-		204,550		-		204,550
Non-employee stock warrant awards		68,590		-		100,605		84,605
	$	661,132	$	206,760	$	700,909	$	496,836

XML 35 R24.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - USD ($) $ in Millions	Sep. 30, 2020	May 29, 2020
Significant Accounting Policies (Details) [Line Items]
Escrow Deposit	$ 0.2	$ 0.2
Minimum [Member]
Significant Accounting Policies (Details) [Line Items]
Ownership interest, percentage	3.00%
Maximum [Member]
Significant Accounting Policies (Details) [Line Items]
Ownership interest, percentage	5.00%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - Schedule of cash and restricted cash total as presented in the condensed statements of cash flows - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Schedule of cash and restricted cash total as presented in the condensed statements of cash flows [Abstract]
Cash	$ 4,120,565	$ 1,690,866	$ 3,214,945
Restricted cash		200,000	200,000
Total cash and restricted cash	$ 4,120,565	$ 1,890,866	$ 3,414,945

XML 37 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - Schedule of anti-dilutive impact on net loss - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,986,994	1,047,974
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,235,266	1,032,692
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	739,212
Non-vested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	12,516	15,282

XML 38 R27.htm IDEA: XBRL DOCUMENT

License Agreements (Details) - USD ($)				1 Months Ended					9 Months Ended
License Agreements (Details) - USD ($)	May 14, 2020	Jun. 01, 2019	Mar. 08, 2019	Jul. 30, 2020	Feb. 27, 2020	Nov. 20, 2019	Aug. 19, 2019	May 18, 2018	Sep. 30, 2020	Feb. 01, 2020
License Agreements (Details) [Line Items]
Commercial evaluation sublicense and option agreement description			the Company entered into a commercial evaluation sublicense and option agreement (the “Commercial Evaluation Sublicense and Option Agreement”) with the University of Maryland, Baltimore (“UMB”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”). Pursuant to the agreement, the Company paid an initial option and material access fee of $5,000 to UMB and $5,000 to Isoprene.
Sublicense Agreement, description									The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred in a private financing that results in gross proceeds of at least $5 million.
George Washington University [Member]
License Agreements (Details) [Line Items]
Sponsored research agreement, description		Pursuant to the terms of the Sponsored Research Agreement, GW granted the Company a non-exclusive license to certain of GW’s intellectual property. The Company has agreed to pay GW for all costs incurred in connection with the research; provided, however, such costs shall not exceed approximately $0.5 million
License initiation fee					$ 10,000
Licensed product, description					(i) $75,000 per year for the development and commercialization of the GW Licensed Product, (ii) $2,000 for license maintenance fees on the first anniversary of the Effective Date and (iii) $5,000 for license maintenance fees commencing on the second anniversary of the Effective Date and thereafter. Furthermore, the Company shall be required to pay GW a sublicense fee equal to a certain percentage of the sum of payments plus the fair market value of all other consideration of any kind received by the Company from sublicensees during each quarter as follows: a 40% sublicense fee until the first anniversary of the Effective Date, a 30% sublicense fee until the third anniversary of the Effective Date and a 20% sublicense fee after the third anniversary of the Effective Date; provided, however, such sublicense fee shall exclude certain fees paid to the Company such as certain royalties, equity investments, loan proceeds and sponsored research funding. The Company shall also pay GW milestone payments of up to an aggregate of $90,000 and sales-based royalties at a low single digit percentage, subject to certain minimum royalty requirements. In addition, during each Option Exercise Period and Renewal Period (as defined in the Research Option Agreement) the Company shall pay GW, on a quarterly basis, for all costs and expenses related to the GW Licensed Patents (the “Patent Costs”).
North Carolina State University [Member]
License Agreements (Details) [Line Items]
License initiation fee						$ 25,000
North Carolina State University [Member] \| Minimum [Member]
License Agreements (Details) [Line Items]
Annual royalty fee						0
North Carolina State University [Member] \| Maximum [Member]
License Agreements (Details) [Line Items]
Milestone payments						585,000
Annual royalty fee						$ 50,000
Virginia Commonwealth University [Member]
License Agreements (Details) [Line Items]
Annual license fee									$ 50,000
Assignment Agreement [Member]
License Agreements (Details) [Line Items]
Milestone payments	$ 3,500,000
Licensed Patents [Member] \| George Washington University [Member]
License Agreements (Details) [Line Items]
Patents paid										$ 2,500
Isoprene Sublicense Agreement [Member]
License Agreements (Details) [Line Items]
Licensed product, description				Pursuant to the Isoprene Sublicense Agreement, the Company shall pay Isoprene, among other things, (i) a license fee, (ii) a royalty rate at a middle single digit percentage, (iii) milestone payments of up to $1,375,000 and (iv) revenue interest at a low single digit percentage based on the net revenue of covered products sold by Isoprene during the Isoprene Term.
License agreement [Member] \| University Of Cincinnati [Member]
License Agreements (Details) [Line Items]
Milestone payments								$ 120,000
Initial fee								5,000
Annual license fee								$ 5,000
Expires license term								10 years
Chelexa BioSciences, Inc. [Member] \| University Of Cincinnati [Member]
License Agreements (Details) [Line Items]
Milestone payments	$ 6,000
Isoprene-Hoth Option [Member]
License Agreements (Details) [Line Items]
Option exercise fee			$ 20,000
UMD-Hoth Option [Member]
License Agreements (Details) [Line Items]
Option exercise fee			$ 20,000
Zylö Therapeutics Inc. [Member]
License Agreements (Details) [Line Items]
Sublicense Agreement, description							upfront license fee of $50,000 and is required to pay Zylö (i) sales-based royalties at percentages which range from high single digits to low double digits, with low sales volumes being subject to lower royalty rates; and (ii) total milestone payments of up to $13.5 million. In addition, in connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 30,000 shares of Zylö’s Class B common stock for $60,000.

XML 39 R28.htm IDEA: XBRL DOCUMENT

License Agreements (Details) - Schedule of research and development expenses for licenses acquired - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total	$ 231,090	$ 50,000	$ 625,605	$ 70,000
The George Washington University [Member]
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total	153,590	2,500	195,605	2,500
Isoprene Pharmaceuticals, Inc. [Member]
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total	30,000		30,000
University of Cincinnati [Member]
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total	17,500	7,500	35,000	7,500
University of Maryland and Isoprene Pharmaceuticals, Inc. [Member]
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total				10,000
Virginia Commonwealth University [Member]
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total	30,000		365,000
Zylö Therapeutics, Inc. [Member]
License Agreements (Details) - Schedule of research and development expenses for licenses acquired [Line Items]
Total		$ 40,000		$ 50,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note Receivable (Details)	9 Months Ended
Note Receivable (Details)	Sep. 30, 2020 USD ($)
Premiums Receivable Disclosure [Abstract]
Convertible promissory note	$ 50,000
Sublicense agreement, description	The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred in a private financing that results in gross proceeds of at least $5 million.
Conversion price, description	(i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization Isoprene immediately prior to the conversion of the Isoprene Note.

XML 41 R30.htm IDEA: XBRL DOCUMENT

Related Party (Details)	Sep. 30, 2020 USD ($) shares
Common Stock [Member]
Related Party (Details) [Line Items]
Common stock issued shares (in Shares) \| shares	7,350
Director [Member]
Related Party (Details) [Line Items]
Received in cash compensation	$ 22,500
Director [Member] \| AIkido Pharma Inc. [Member]
Related Party (Details) [Line Items]
Received in cash compensation	$ 8,700

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Assets (Details) - Schedule of assets and liabilities measured at fair value - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Assets
Marketable securities - mutual funds	$ 1,290,022	$ 803,664
Quoted prices in active markets (Level 1) [Member]
Assets
Marketable securities - mutual funds	1,290,022	803,664
Significant other observable inputs (Level 2) [Member]
Assets
Marketable securities - mutual funds
Significant unobservable inputs (Level 3) [Member]
Assets
Marketable securities - mutual funds

XML 43 R32.htm IDEA: XBRL DOCUMENT

Investment in HaloVax (Details)	1 Months Ended
Investment in HaloVax (Details)	May 28, 2020	Mar. 23, 2020
Investment In Halovax [Abstract]
Description of investment	the Company entered into a membership interest purchase agreement to purchase 1% of HaloVax’s outstanding membership interest for a purchase price of $100,000.	the Company and HaloVax entered into a Membership Interest Purchase Agreement pursuant to which the Company purchased 5% of HaloVax’s outstanding membership interests for $250,000 on March 27, 2020 (the “Initial Closing Date”) and shall have the option to purchase up to an additional 25% of HaloVax’s membership interests (for $3,000,000 (inclusive of the $250,000)), which option shall expire 30 days after the Initial Closing Date.

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($)							1 Months Ended							3 Months Ended	9 Months Ended
Stockholders' Equity (Details) - USD ($)	Aug. 10, 2020	Jul. 15, 2020	Jul. 08, 2020	Jun. 03, 2020	Mar. 06, 2020	Feb. 05, 2020	Jul. 21, 2020	May 21, 2020	May 18, 2020	Apr. 15, 2020	Mar. 24, 2020	Feb. 27, 2020	Jan. 17, 2020	Sep. 30, 2020	Sep. 30, 2020
Stockholders' Equity (Details) [Line Items]
Common stock upon exercise of warrants issued													15,000
Common stock upon exercise of warrants issued (in Dollars)														$ (2,829)	$ (3,491)
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock upon exercise of warrants issued				12,500	25,000				6,250	3,333
Common stock upon exercise of warrants issued (in Dollars)						$ 12,500
Gross proceeds (in Dollars)				$ 12,500	$ 25,000	$ 12,500			$ 6,250
Issuance of shares															7,350
Stock Options [Member]
Stockholders' Equity (Details) [Line Items]
Warrants to purchase of common stock shares		35,000					200,000
Warrants exercise price (in Dollars per share)			$ 2.54				$ 3.05
Stock option fair value (in Dollars)			$ 100,000				$ 500,000
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Warrants to purchase of common stock shares	72,463											22,988
Warrants exercise price (in Dollars per share)	$ 2.76											$ 4.35
Warrants, description	The August Warrants vest as follows: 20% upon the August Warrant Date of Issuance and the balance, or 80% of the August Warrants shall vest in four equal annual installments of 20% on each anniversary of the August Warrant Date of Issuance.											The February Warrants vest as follows: 20% upon the February Warrant Date of Issuance and the balance, or 80% of the February Warrants shall vest in four equal annual installments of 20% on each anniversary of the February Warrant Date of Issuance.
Warrant [Member] \| Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Warrants to purchase												72,464
Warrant [Member] \| Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Warrants to purchase												90,909
2018 Equity Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Issuance of shares								3,333
Public Offering of Securities [Member]
Stockholders' Equity (Details) [Line Items]
Underwritten public offering (in Dollars)								$ 1,818,182			$ 1,449,275
Public offering price (in Dollars per share)								$ 2.75			$ 3.45
Net proceeds received (in Dollars)								$ 4,500,000			$ 4,200,000
Warrants to purchase								90,909			72,464
Private Placement of Securities, description											the Company’s common stock, representing 5% of the aggregate number of Shares sold in the offering. The warrants will be exercisable for a period of five years from the UA Effective Date at a price per share equal to $4.14 (120% of the public offering price per Share) and are exercisable on a “cashless” basis. The Company has reimbursed Laidlaw for certain of its out-of-pocket expenses incurred in connection with the offering.
Warrants term								5 years
Warrant exercisable price (in Dollars per share)								$ 2.75
Two Directors [Member] \| 2018 Equity Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Unrecognized stock-based compensation expense (in Dollars)														$ 12,000	$ 12,000
Director [Member]
Stockholders' Equity (Details) [Line Items]
Weighted average remaining contractual terms of unvested restricted stock															1 year 171 days
Stock Options [Member]
Stockholders' Equity (Details) [Line Items]
Warrants to purchase of common stock shares			49,212

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of restricted stock awards activities under the Company's 2018 Equity Incentive Plan	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Schedule of restricted stock awards activities under the Company's 2018 Equity Incentive Plan [Abstract]
Number of Units, Nonvested Beginning Balance \| shares	13,200
Weighted Average Grant Day Fair Value, Nonvested Beginning balance \| $ / shares	$ 0.25
Number of Units, Nonvested Ending Balance \| shares	12,516
Weighted Average Grant Day Fair Value, Nonvested Ending balance \| $ / shares	$ 1.47
Number of Units, Granted \| shares	6,666
Weighted Average Grant Day Fair Value, Granted \| $ / shares	$ 3.00
Number of Units, Vested \| shares	(7,350)
Weighted Average Grant Day Fair Value, Vested \| $ / shares	$ 0.66

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of stock option plan - Restricted Stock Awards [Member]	9 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Stockholders' Equity (Details) - Schedule of stock option plan [Line Items]
Number of Shares, Outstanding Beginning Balance \| shares	525,000
Weighted Average Exercise Price, Outstanding Beginning Balance \| $ / shares	$ 5.32
Total Intrinsic Value, Outstanding Beginning Balance \| $	$ 457,250
Weighted Average Remaining Contractual Life, Outstanding Beginning Balance	9 years 146 days
Number of Shares, Ending Balance \| shares	739,212
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 4.52
Total Intrinsic Value, Ending Balance \| $
Weighted Average Remaining Contractual Life, Ending Balance	9 years
Number of Shares, Options vested and exercisable \| shares	739,212
Weighted Average Exercise Price, Options vested and exercisable \| $ / shares	$ 4.52
Total Intrinsic Value, Options vested and exercisable \| $
Weighted Average Remaining Contractual Life, Options vested and exercisable	9 years
Number of Shares, Employee options issued \| shares	200,000
Weighted Average Exercise Price, Employee options issued \| $ / shares	$ 3.05
Total Intrinsic Value, Employee options issued \| $
Weighted Average Remaining Contractual Life, Employee options issued	9 years 292 days
Number of Shares, Non - employee options issued \| shares	49,212
Weighted Average Exercise Price, Non - employee options issued \| $ / shares	$ 2.54
Total Intrinsic Value, Non - employee options issued \| $
Weighted Average Remaining Contractual Life, Non - employee options issued	9 years 292 days
Number of Shares, Forfeited \| shares	(35,000)
Weighted Average Exercise Price, Forfeited \| $ / shares
Total Intrinsic Value, Forfeited \| $
Weighted Average Remaining Contractual Life, Forfeited

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of warrant activity - Warrants [Member]	9 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Stockholders' Equity (Details) - Schedule of warrant activity [Line Items]
Number of Warrants, Outstanding	1,032,692
Weighted Average Exercise Price, Outstanding (in Dollars per share) \| $ / shares	$ 2.91
Total Intrinsic Value, Outstanding (in Dollars) \| $	$ 3,725,745
Weighted Average Remaining Contractual Life,Outstanding	4 years 73 days
Number of Warrants, Issued	258,824
Weighted Average Exercise Price, Issued (in Dollars per share) \| $ / shares	$ 3.28
Total Intrinsic Value, Issues (in Dollars) \| $
Weighted Average Remaining Contractual Life, Issued	5 years 73 days
Number of Warrants, Exercised	(56,250)
Weighted Average Exercise Price, Exercised (in Dollars per share) \| $ / shares	$ 1.00
Total Intrinsic Value, Exercised (in Dollars) \| $
Weighted Average Remaining Contractual Life, Exercised
Number of Warrants, Outstanding	1,235,266
Weighted Average Exercise Price, Outstanding (in Dollars per share) \| $ / shares	$ 3.07
Total Intrinsic Value, Outstanding (in Dollars) \| $	$ 696,334
Weighted Average Remaining Contractual Life, Outstanding	3 years 255 days
Number of Warrants, Warrants exercisable	1,158,906
Weighted Average Exercise Price, Warrants exercisable	3.07
Total Intrinsic Value, Warrants exercisable (in Dollars) \| $	$ 696,334
Weighted Average Remaining Contractual Life, Warrants exercisable	3 years 255 days

XML 48 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Stock-based compensation	$ 661,132	$ 206,760	$ 700,909	$ 496,836
Restricted Stock Awards [Member] \| Employee common stock awards [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Stock-based compensation	487,963		487,963	199,182
Restricted Stock Awards [Member] \| Non-employee stock option awards [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Stock-based compensation	100,104		100,104
Restricted Stock Awards [Member] \| Employee restricted stock awards [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Stock-based compensation	4,475	2,210	12,237	8,499
Restricted Stock Awards [Member] \| Non-employee restricted stock awards [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Stock-based compensation		204,550		204,550
Restricted Stock Awards [Member] \| Non-employee warrant awards [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Stock-based compensation	$ 68,590		$ 100,605	$ 84,605

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Leases office space	$ 2,000
Rent expense	$ 19,000	$ 24,000

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 158 296 1 false 44 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://hoththerapeutics.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://hoththerapeutics.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://hoththerapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://hoththerapeutics.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Sheet http://hoththerapeutics.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) (Parentheticals) Sheet http://hoththerapeutics.com/role/ShareholdersEquityType2or3_Parentheticals Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://hoththerapeutics.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business Operations Sheet http://hoththerapeutics.com/role/OrganizationandDescriptionofBusinessOperations Organization and Description of Business Operations Notes 8 false false R9.htm 008 - Disclosure - Significant Accounting Policies Sheet http://hoththerapeutics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - License Agreements Sheet http://hoththerapeutics.com/role/LicenseAgreements License Agreements Notes 10 false false R11.htm 010 - Disclosure - Note Receivable Sheet http://hoththerapeutics.com/role/NoteReceivable Note Receivable Notes 11 false false R12.htm 011 - Disclosure - Related Party Sheet http://hoththerapeutics.com/role/RelatedParty Related Party Notes 12 false false R13.htm 012 - Disclosure - Fair Value of Financial Assets Sheet http://hoththerapeutics.com/role/FairValueofFinancialAssets Fair Value of Financial Assets Notes 13 false false R14.htm 013 - Disclosure - Investment in HaloVax Sheet http://hoththerapeutics.com/role/InvestmentinHaloVax Investment in HaloVax Notes 14 false false R15.htm 014 - Disclosure - Stockholders' Equity Sheet http://hoththerapeutics.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 015 - Disclosure - Commitments and Contingencies Sheet http://hoththerapeutics.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Risk and Uncertainties Sheet http://hoththerapeutics.com/role/RiskandUncertainties Risk and Uncertainties Notes 17 false false R18.htm 017 - Disclosure - Subsequent Events Sheet http://hoththerapeutics.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://hoththerapeutics.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://hoththerapeutics.com/role/SignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - Significant Accounting Policies (Tables) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://hoththerapeutics.com/role/SignificantAccountingPolicies 20 false false R21.htm 020 - Disclosure - License Agreements (Tables) Sheet http://hoththerapeutics.com/role/LicenseAgreementsTables License Agreements (Tables) Tables http://hoththerapeutics.com/role/LicenseAgreements 21 false false R22.htm 021 - Disclosure - Fair Value of Financial Assets (Tables) Sheet http://hoththerapeutics.com/role/FairValueofFinancialAssetsTables Fair Value of Financial Assets (Tables) Tables http://hoththerapeutics.com/role/FairValueofFinancialAssets 22 false false R23.htm 022 - Disclosure - Stockholders' Equity (Tables) Sheet http://hoththerapeutics.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://hoththerapeutics.com/role/StockholdersEquity 23 false false R24.htm 023 - Disclosure - Significant Accounting Policies (Details) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables 24 false false R25.htm 024 - Disclosure - Significant Accounting Policies (Details) - Schedule of cash and restricted cash total as presented in the condensed statements of cash flows Sheet http://hoththerapeutics.com/role/ScheduleofcashandrestrictedcashtotalaspresentedinthecondensedstatementsofcashflowsTable Significant Accounting Policies (Details) - Schedule of cash and restricted cash total as presented in the condensed statements of cash flows Details http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 025 - Disclosure - Significant Accounting Policies (Details) - Schedule of anti-dilutive impact on net loss Sheet http://hoththerapeutics.com/role/ScheduleofantidilutiveimpactonnetlossTable Significant Accounting Policies (Details) - Schedule of anti-dilutive impact on net loss Details http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 026 - Disclosure - License Agreements (Details) Sheet http://hoththerapeutics.com/role/LicenseAgreementsDetails License Agreements (Details) Details http://hoththerapeutics.com/role/LicenseAgreementsTables 27 false false R28.htm 027 - Disclosure - License Agreements (Details) - Schedule of research and development expenses for licenses acquired Sheet http://hoththerapeutics.com/role/ScheduleofresearchanddevelopmentexpensesforlicensesacquiredTable License Agreements (Details) - Schedule of research and development expenses for licenses acquired Details http://hoththerapeutics.com/role/LicenseAgreementsTables 28 false false R29.htm 028 - Disclosure - Note Receivable (Details) Sheet http://hoththerapeutics.com/role/NoteReceivableDetails Note Receivable (Details) Details http://hoththerapeutics.com/role/NoteReceivable 29 false false R30.htm 029 - Disclosure - Related Party (Details) Sheet http://hoththerapeutics.com/role/RelatedPartyDetails Related Party (Details) Details http://hoththerapeutics.com/role/RelatedParty 30 false false R31.htm 030 - Disclosure - Fair Value of Financial Assets (Details) - Schedule of assets and liabilities measured at fair value Sheet http://hoththerapeutics.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueTable Fair Value of Financial Assets (Details) - Schedule of assets and liabilities measured at fair value Details http://hoththerapeutics.com/role/FairValueofFinancialAssetsTables 31 false false R32.htm 031 - Disclosure - Investment in HaloVax (Details) Sheet http://hoththerapeutics.com/role/InvestmentinHaloVaxDetails Investment in HaloVax (Details) Details http://hoththerapeutics.com/role/InvestmentinHaloVax 32 false false R33.htm 032 - Disclosure - Stockholders' Equity (Details) Sheet http://hoththerapeutics.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://hoththerapeutics.com/role/StockholdersEquityTables 33 false false R34.htm 033 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock awards activities under the Company's 2018 Equity Incentive Plan Sheet http://hoththerapeutics.com/role/ScheduleofrestrictedstockawardsactivitiesundertheCompanys2018EquityIncentivePlanTable Stockholders' Equity (Details) - Schedule of restricted stock awards activities under the Company's 2018 Equity Incentive Plan Details http://hoththerapeutics.com/role/StockholdersEquityTables 34 false false R35.htm 034 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option plan Sheet http://hoththerapeutics.com/role/ScheduleofstockoptionplanTable Stockholders' Equity (Details) - Schedule of stock option plan Details http://hoththerapeutics.com/role/StockholdersEquityTables 35 false false R36.htm 035 - Disclosure - Stockholders' Equity (Details) - Schedule of warrant activity Sheet http://hoththerapeutics.com/role/ScheduleofwarrantactivityTable Stockholders' Equity (Details) - Schedule of warrant activity Details http://hoththerapeutics.com/role/StockholdersEquityTables 36 false false R37.htm 036 - Disclosure - Stockholders' Equity (Details) - Schedule of stock-based compensation expense Sheet http://hoththerapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable Stockholders' Equity (Details) - Schedule of stock-based compensation expense Details http://hoththerapeutics.com/role/StockholdersEquityTables 37 false false R38.htm 037 - Disclosure - Commitments and Contingencies (Details) Sheet http://hoththerapeutics.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://hoththerapeutics.com/role/CommitmentsandContingencies 38 false false All Reports Book All Reports hoth-20200930.xml hoth-20200930.xsd hoth-20200930_cal.xml hoth-20200930_def.xml hoth-20200930_lab.xml hoth-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 55 0001213900-20-036191-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-036191-xbrl.zip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end